



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 271/06, 453/02, 413/12 C07D 413/06, 271/00 A61K 31/41, 31/445	A1	(11) International Publication Number: WO 93/13083 (43) International Publication Date: 8 July 1993 (08.07.93)
(21) International Application Number: PCT/JP92/01658 (22) International Filing Date: 18 December 1992 (18.12.92) (30) Priority data: 9127533.9 31 December 1991 (31.12.91) GB 9220904.8 5 October 1992 (05.10.92) GB (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only) : TAKASUGI, Hisashi [JP/JP]; 3-116-10, Mozu Umekita, Sakai-shi, Osaka 591 (JP). KUNO, Atsushi [JP/JP]; 24-6, Shinkofudai 5-chome, Toyono-cho, Toyono-gun, Osaka 563-01 (JP). OHKUBO, Mitsuru [JP/JP]; 5-1-65, Fushimidai, Inagawa-cho, Kawabe-gun, Hyogo 666-02 (JP).		(74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP). (81) Designated States: AU, CA, HU, JP, KR, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY <div style="text-align: center;"> $\begin{array}{c} R^4 \\ \\ -CON- \end{array} \quad (a)$ </div> <div style="text-align: center;"> $\begin{array}{c} R^8 \\ \\ -CH- \end{array} \quad (b)$ </div> (57) Abstract <p>Heterocyclic compounds of the formula: R¹-Q-Z-X-A-M, wherein R¹ is lower alkyl, a heterocyclic group which may have suitable substituent(s), etc; Q is oxadiazole, Z is bond or vinyl, X is bond, a group of formula (a), (in which R⁴ is hydrogen or lower alkyl), a group of formula (b), (in which R⁸ is hydroxy or protected hydroxy), etc; A is bond, lower alkylene or lower alkenylene and M is a heterocyclic group containing at least one nitrogen atom which may have one substituent selected from the group consisting of lower alkyl, an imino protective group and ar(lower)alkyl which may have suitable substituent(s), and a pharmaceutically acceptable salt thereof which are useful as a medicament.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DESCRIPTION

OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY

5

TECHNICAL FIELD

10 This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

DISCLOSURE OF INVETION

15

This invention relates to new heterocyclic compounds. More particularly, this invention relates to new oxadiazole derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, processes for preparation thereof, a pharmaceutical composition comprising the same and a use of the same.

20 Accordingly, one object of this invention is to provide the new and useful oxadiazole derivatives and pharmaceutically acceptable salts thereof which possess an acetylcholinesterase-inhibitory activity and muscarinic agonist activity.

25 Another object of this invention is to provide processes for preparation of the oxadiazole derivatives and their salts thereof.


30 A further object of this invention is to provide a pharmaceutical composition comprising said oxadiazole derivatives or a pharmaceutically acceptable salt thereof.

35 Still further object of this invention is to provide a use of said oxadiazole derivative or a pharmaceutically

acceptable salt thereof as a medicament for prophylactic and therapeutic treatment of disorders in the central nervous system such as amnesia, dementia [e.g. senile dementia of Alzheimer type, vascular dementia etc.],
 5 cerebrovascular disease, in human being and animals.

The object oxadiazole derivatives of the present invention are novel and represented by the following general formula (I) :

10



wherein R^1 is lower alkyl, a heterocyclic group which may have suitable substituent(s), aryl which
 15 may have suitable substituent(s),
 ar(lower)alkyl which may have suitable substituent(s), or ar(lower)alkenyl which may have suitable substituent(s),

20 Q is oxadiazolediyl,

Z is bond or vinyl,

X is bond,

a group of the formula :



25

(in which R^4 is hydrogen or lower alkyl),
 a group of the formula :



30

(in which R^8 is hydroxy or protected hydroxy),



35

-NHCO-


A is bond, lower alkylene or lower alkynylene and
 M is a heterocyclic group containing at least one
 nitrogen atom which may have one substituent
 selected from the group consisting of lower
 alkyl, an imino protective group and
 ar(lower)alkyl which may have suitable
 substituent(s).

The object compound (I) of the present invention can
 be prepared by the following processes.

Process (1)


(II)

or its reactive derivative
 at the carboxy group,
 or a salt thereof




(III)

or its reactive derivative
 at the amino group,
 or a salt thereof



(Ia)

or a salt thereof


Process (2)

5

(IV)

or its reactive derivative
at the amino group,
or a salt thereof

10



(V)

15

or its reactive derivative
at the carboxy group,
or a salt thereof




20

(Ib)

or a salt thereof

Process (3)


25



(VI)

or a salt thereof


30



(VII)

35

or a salt thereof




5

(Ic)

or a salt thereof

Process (4)


10




(Ia)

or a salt thereof

15



20




25

(Id)

or a salt thereof

Process (5)

30




(XVI)

35

or a salt thereof


reduction

5



(Ie)

or a salt thereof

10 Process (6)


(If)

15

or a salt thereof

elimination reaction of the
imino protective group

20




(Ig)

25

or a salt thereof

Process (7)

30




(XVII)

or a salt thereof

35


reduction



(Ih)

or a salt thereof


Process (8)



(Ii)


or a salt thereof

elimination reaction of the
hydroxy protective group



(Ij)

or a salt thereof

Process (9)

5

(Ij)


or a salt thereof

10

oxidation




15



(Ik)

or a salt thereof

20


Process (10)

25

(XXV)

or a salt thereof

30




(XXXXVI)

or a salt thereof

35





(II)

5

or a salt thereof

wherein R^1 , Q, Z, A, X and M are each as defined above,

R^2 is lower alkyl, an imino protective group,
or ar(lower)alkyl which may have suitable
substituent(s),

10

R^3 is a leaving group,

R^4 is lower alkyl,

R^7 is hydrogen, (C_1-C_5) alkyl, aryl which may have
suitable substituent(s), or ar(C_1-C_5)alkyl
which may have suitable substituent(s),

15

R^8 is protected hydroxy,

Y^1 is acid residue,

$W^{1\ominus}$, $W^{2\ominus}$ and $W^{3\ominus}$ are each anion,

M^1 is a heterocyclic group containing at least one
nitrogen atom which has an imino protective
group,

20

M^2 is a heterocyclic group containing at least one
nitrogen atom and


$\text{---} \bigcirc \text{NH}$ is a saturated heterocyclic group containing at
least one nitrogen atom.

25

The starting compounds can be prepared by the
following Processes.

30

35

Process (A)


5

(IX)

or a salt thereof

cyclization

10




15

(IIa)

or a salt thereof

Process (B)


20



(X)

or a salt thereof


25



(XI)

or a salt thereof


30




(XII)

35

or a salt thereof




5



(XIIIa)

or a salt thereof


10 Process (C)

(XIII)


15

or a salt thereof

20



25




(VII)

or a salt thereof

Process (D)

30




(IIb)

or a salt thereof

35

↓ oxidation




5

(IIc)

or a salt thereof

Process (E)

10




(Im)

or a salt thereof

15

↓ $\text{R}^7\text{-CHO}$
(XV)
or a salt thereof

20




25

(XVI)

or a salt thereof

Process (F)


30



(XVIII)


35

or a salt thereof



(XIX)


or its reactive derivative at the
carboxy group, or a salt thereof



(IX)

or a salt thereof

15

Process (G)

(IIId)


20

or a salt thereof



reduction

25



(XX)


30

or a salt thereof



oxidation


35



(XXI)

or a salt thereof

5


Process (H)

10


(XXIa)

or a salt thereof

15



20




25

(XXIII)

or a salt thereof

Process (I)

30



(II)

or its reactive derivative
at the carboxy group,
or a salt thereof

35




(XXIV)

or its reactive derivative at the
amino group, or a salt thereof




(XXVa)

or a salt thereof

Process (J)


(In)

or a salt thereof




(XXVI)

or a salt thereof



(XVIIa)

or a salt thereof


Process (K)

5

(XXVII)

or a salt thereof

10




(XXVIII)

or a salt thereof



15



20

(IIe)

or a salt thereof

Process (L)


25



(XXIX)


or a salt thereof

30




35

(XXX)




(XXXI)

(2)




(XXXII)

or a salt thereof




(XXXIIIa)

or a salt thereof

Process (M)

(XXXIIIb)

or a salt thereof



(XXXIV)


or a salt thereof

ii) reduction



(XXXIIIc)

or a salt thereof

Process (N)

5

(XXXIIIB)
or a salt thereof



acylation

10



15

(XXXIIID)
or a salt thereof

Process (O)

20



(XXXIIID)
or a salt thereof

25



reduction

30



(XXXIIIE)
or a salt thereof

35


Process (P)

5


(XXXV)

or a salt thereof

10




15



(XXXVII)

or a salt thereof

20

Process (Q) - ①


25

(XXXVII)

or a salt thereof

30


reduction



(XXXVIIIa)

35

or a salt thereof

Process (Q) - (2)


5

(XXXVIII)
or a salt thereof




reduction

10



15

(XXXIX)
or a salt thereof

Process (R)

20

(XXXX)
or a salt thereof




(XXXXI)

or a salt thereof


25

30




(XXXXII)
or a salt thereof

35





(XXXIX)
or a salt thereof

10 Process (S)




15 (XXXXIII)
or a salt thereof



30 (VII)
or a salt thereof

35

2




(XIX)

or its reactive derivative
at the carboxy group,
or a salt thereof

5

10



(XXXXIV)

15

or a salt thereof

Process (T)

20




(XXXXV)

or a salt thereof

25

cyclization

30



(IIIf)

or a salt thereof

35

wherein R^1 , R^2 , R^7 , X , Z , A , M , M^2 , Q , $W^{1\ominus}$ and $\text{---}\text{C}\text{---}\text{NH}$ are each as defined above,

R_a^1 is aryl having lower alkylthio,

R_b^1 is aryl having lower alkylsulfinyl, or aryl having lower alkylsulfonyl,

R^5 is carboxy or protected carboxy,

R^6 is aryl,

R^9 is lower alkyl,

R^{10} is hydroxy, protected hydroxy, amino or protected amino,

R^{11} is protected carboxy,

A^1 is bond or C_1 - C_5 alkylene,

Y^2 is acid residue,

Y^3 and W_a^2 are each a leaving group,

Y^4 is hydroxy or a leaving group,

J is an alkali metal,

M^3 is a heterocyclic group containing at least one nitrogen atom which has a substituent selected from the group consisting of lower alkyl and ar(lower)alkyl which may have suitable substituent(s),

M^4 is a heterocyclic group containing at least one nitrogen atom which has a substituent selected from the group consisting of $(C_1$ - C_5)alkanoyl, aroyl which may have suitable substituent(s) and ar(C_1 - C_5)alkanoyl which may have suitable substituent(s),

M^5 is a heterocyclic group containing at least one nitrogen atom which has a substituent selected from the group consisting of lower alkyl and ar(lower)alkyl which may have suitable substituent(s).

Suitable pharmaceutically acceptable salts of the

object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g. triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g. formate, acetate, trifluoroacetate, melete, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.).

In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.

The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.

The term "higher" is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.

Suitable "lower alkyl" and "lower alkyl moiety" in the terms "ar(lower)alkyl", "lower alkylthio", "lower alkylsulfinyl" and "lower alkylsulfonyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, and the like, preferably one having 1 to 4 carbon atom(s).

Suitable "lower alkylene" may be straight or branched one having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene, and the like, preferably
5 one having 1 to 4 carbon atom(s).

Suitable "lower alkynylene" may include ethynylene, propynylene, 1-(or 2-)butynylene, 1-(or 2- or 3-)pentynylene, and the like.

Suitable "aryl" and "aryl moiety" in the terms
10 "ar(lower)alkyl" "ar(lower)alkenyl", "ar(C₁-C₅)alkyl" and "ar(C₁-C₅)alkanoyl" may include phenyl, naphthyl and the like, in which more preferable example may be phenyl.

Suitable "heterocyclic group" may include saturated or unsaturated, monocyclic or polycyclic heterocyclic
15 group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like.

And, especially preferable heterocyclic group may be heterocyclic group such as

unsaturated 3 to 8-membered (more preferably 5 or
20 6-membered) heteromonocyclic group containing 1 to 4-nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl,
25 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl,
30 piperidyl, piperazinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyll, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.;

35 unsaturated 3 to 8-membered (more preferably 5 or 6-

- membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.;
- 5 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;
- unsaturated condensed heterocyclic group containing 1 to 2
- 10 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;
- unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2
- 15 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;
- saturated 3 to 8-membered (more preferably 5 or
- 20 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;
- unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2
- 25 sulfur atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.;
- unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;
- 30 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;
- unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen
- 35 atom and 1 to 2 sulfur atom(s), for example,


dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;

- 5 unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.;

saturated heterobicyclic group of the formula :

10



(wherein l , m and n are each integer of 1 to 6); and the like.

- 15 Suitable "substituent" in the term "heterocyclic group which may have suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, t-butoxy, pentyloxy, neopentyloxy, t-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1-methylpropargyl, 1 or 2 or 3-butyne, 1 or 2 or 3 or 4-pentyne, 1 or 2 or 3 or 4 or 5-hexyne, etc.), mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, etc.), halogen (e.g., chlorine, bromine, fluorine, iodine), carboxy, protected carboxy, hydroxy, protected hydroxy, aryl (e.g., phenyl, naphthyl,
- 20
- 25
- 30
- 35

etc.), ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl, phenethyl, phenylpropyl, etc.), carboxy(lower)alkyl, protected carboxy(lower)alkyl, nitro, amino, protected amino, di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylmethylamino, ethylpropylamino, etc.), hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl, cyano, mercapto, lower alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, etc.), imino, and the like.

Suitable "heterocyclic group containing at least one nitrogen atom" may include

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4-nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, tetrahydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.; unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.; and the like.

Suitable "saturated heterocyclic group" in the term "saturated heterocyclic group containing at least one nitrogen atom" may include

saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) (e.g., azetidiny, pyrrolidinyl, imidazolidinyl, piperidyl, pyrazolidinyl,

piperazinyl, etc.) and the like.

Suitable "alkali metal" may include potassium, sodium and the like.

Suitable "leaving group" may include lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy, etc.), aryloxy (e.g. phenoxy, naphthoxy, etc.), an acid residue or the like.

Suitable "acid residue" may be halogen (e.g. chlorine, bromine, iodine, etc.), sulfonyloxy (e.g. methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy, etc.) or the like.

Suitable "substituent" in the terms "aryl which may have suitable substituent(s)", "ar(lower)alkyl which may have suitable substituent(s)", "ar(lower)alkenyl which may have suitable substituent(s)" and "ar(C₁-C₅)alkyl which may have suitable substituent(s)" "aroxy which may have suitable substituent(s)" and "ar(C₁-C₅)alkanoyl which may have suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1 or 2 or 3-butyne, 1 or 2 or 3 or 4-pentyne, 1 or 2 or 3 or 4 or 5-hexyne, etc.), mono(or di or tri)halo(lower)alkyl (e.g. fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, etc.), halogen (e.g., chlorine, bromine, fluorine and iodine), carboxy,

protected carboxy, hydroxy, protected hydroxy, aryl (e.g., phenyl, naphthyl, etc.), ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl, phenethyl, phenylpropyl, etc.), carboxy(lower)alkyl wherein lower alkyl moiety can be referred to the ones as exemplified above, protected carboxy(lower)alkyl wherein lower alkyl moiety can be referred to the ones as exemplified above and protected carboxy moiety can be referred to the ones as exemplified below, nitro, amino, protected amino, di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylisopropylamino, etc.), hydroxy(lower)alkyl, protected hydroxy-(lower)alkyl, acyl, cyano, mercapto, lower alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, etc.), lower alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, etc.), imino, and the like.

Suitable "(C₁-C₅)alkyl" and "(C₁-C₅)alkyl moiety" in the term "ar(C₁-C₅)alkyl" may include straight or branched one having 1 to 5 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, and the like.

Suitable "protected hydroxy" may include acyloxy and the like.

Suitable "protected amino" may include acylamino and the like.

Suitable "an imino protective group" may include acyl and the like.

Suitable "acyl" and "acyl moiety" in the terms "acyloxy" and "acylamino" may include carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.

Suitable example of said acyl may be illustrated as follows :-

Carbamoyl;

Aliphatic acyl such as lower or higher alkanoyl (e.g. formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);

lower or higher alkoxycarbonyl (e.g. methoxycarbonyl ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);

lower or higher alkylsulfonyl (e.g. methylsulfonyl, ethylsulfonyl, etc.);

lower or higher alkoxysulfonyl (e.g. methoxysulfonyl, ethoxysulfonyl, etc.); or the like;

Aromatic acyl such as

aroyl (e.g. benzoyl, toluoyl, naphthoyl, etc.);

ar(lower)alkanoyl [e.g. phenyl(lower)alkanoyl (e.g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(lower)alkanoyl (e.g. naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];

ar(lower)alkenoyl [e.g. phenyl(lower)alkenoyl (e.g. phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl(lower)alkenoyl (e.g. naphthylpropenoyl, naphthylbutenoyl, naphthylpentenoyl, etc.), etc.];

ar(lower)alkoxycarbonyl [e.g. phenyl(lower)alkoxy-carbonyl (e.g. benzyloxycarbonyl, etc.), etc.];

aryloxycarbonyl (e.g. phenoxycarbonyl, naphthyloxycarbonyl, etc.);

aryloxy(lower)alkanoyl (e.g. phenoxyacetyl, phenoxypropionyl, etc.);

arylcarbamoyl (e.g. phenylcarbamoyl, etc.);

arylthiocarbamoyl (e.g. phenylthiocarbamoyl, etc.);

arylglyoxyloyl (e.g. phenylglyoxyloyl, naphthylglyoxyloyl, etc.);

arenesulfonyl (e.g. benzenesulfonyl, p-toluenesulfonyl, etc.); or the like;

5 Heterocyclic acyl such as
heterocycliccarbonyl;
heterocyclic(lower)alkanoyl (e.g. heterocyclicacetyl,
heterocyclicpropanoyl, heterocyclicbutanoyl,
heterocyclicpentanoyl, heterocyclichexanoyl,
10 etc.);
heterocyclic(lower)alkenoyl (e.g. heterocyclicpropenoyl,
heterocyclicbutenoyl, heterocyclicpentenoyl,
heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl;
or the like; in which suitable heterocyclic moiety in the
15 terms "heterocycliccarbonyl",
"heterocyclic(lower)alkanoyl", heterocyclic(lower)alkenoyl
and "heterocyclicglyoxyloyl" can be referred to the ones
as mentioned above.

 Suitable "lower alkenyl moiety" in the term
20 "ar(lower)alkenyl" may include vinyl, 1-(or 2-)propenyl,
1-(or 2- or 3-)butenyl, 1-(or 2- or 3- or 4-)pentenyl,
1-(or 2- or 3- or 4- or 5-)hexenyl, methylvinyl,
ethylvinyl, 1-(or 2- or 3-)methyl-1-(or 2-)propenyl, 1-(or
2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)-
25 methyl-1-(or 2- or 3-)butenyl, and the like,
in which more preferable example may be C₂-C₄ alkenyl.

 Suitable "oxadiazole-diyl" may include
1,2,4-oxadiazole-diyl, 1,2,5-oxadiazole-diyl and
1,3,4-oxadiazole-diyl.

30 Suitable "C₁-C₅ alkylene" may be straight or branched
one having 1 to 5 carbon atom(s), such as methylene,
ethylene, trimethylene, propylene, tetramethylene,
pentamethylene, and the like.

 Suitable "protected carboxy" may include esterified
35 carboxy and the like. An suitable examples of said ester

moiety may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, t-pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.);

5 lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.);
lower alkynyl ester (e.g., ethynyl ester, propynyl ester, etc.);

10 lower alkoxyalkyl ester (e.g., methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester, 1-methoxyethyl ester 1-ethoxyethyl ester, etc.);
lower alkylthioalkyl ester (e.g., methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester, isopropylthiomethyl ester, etc.);

15 mono(or di or tri)halo(lower)alkyl ester (e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.);
lower alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, 2-acetoxyethyl ester, 2-propionyloxyethyl ester, etc.);

20 lower alkanesulfonyl(lower)alkyl ester (e.g. mesylmethyl ester, 2-mesyloethyl ester, etc.);
ar(lower)alkyl ester, for example, phenyl(lower)alkyl ester which may have one or more suitable substituent(s) (e.g., benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-t-butylbenzyl ester, etc.);

25 aryl ester which may have one or more suitable substituent(s) such as substituted or unsubstituted phenyl ester (e.g., phenyl ester, tolyl ester, t-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, 4-chlorophenyl ester, 4-methoxyphenyl ester, etc.);

30 tri(lower)alkyl silyl ester;

35

lower alkylthioester (e.g. methylthioester, ethylthioester, etc.) and the like.

Suitable "aroyl" may include benzoyl, naphthoyl and the like.

5 Suitable "C₁-C₅ alkanoyl" and "C₁-C₅ alkanoyl moiety" in the term "ar(C₁-C₅)alkanoyl" may include formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl and the like.

10 The processes for preparing the object and starting compounds are explained in detail in the following.

Process (1)

15 The compound (Ia) or a salt thereof can be prepared by reacting the compound (III) or its reactive derivative at the amino group, or a salt thereof with the compound (II) or its reactive derivative at the carboxy group, or a salt thereof.

20 Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound
25 such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide [e.g. N-(trimethylsilyl)-acetamide], bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene, and the like.

30 Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide;
35 a mixed acid anhydride with an acid such as substituted

phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, 5 thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic 10 acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; or an activated ester [e.g. ethyl ester, cyanomethyl ester, methoxymethyl 15 ester, dimethyliminomethyl $[(CH_3)_2N^+=CH-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl 20 thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, 25 N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (II) to be used.

The reaction is usually carried out in a conventional 30 solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence 35 the reaction. These conventional solvent may also be used

in a mixture with water.

In case that the compounds (II) and (III) are in liquid, they can be used as a solvent.

In this reaction, when the compound (II) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

Process (2)

The compound (Ib) or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the amino group, or a salt thereof with the compound
5 (V) or its reactive derivative at the carboxy group, or a salt thereof.

Suitable reactive derivative at the amino group of the compound (IV) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction
10 of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IV) with a silyl compound such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide [e.g.
15 N-(trimethylsilyl)acetamide], bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (IV) with phosphorus trichloride or phosgene, and the like.

Suitable reactive derivative at the carboxy group of the compound (V) may include an acid halide, an acid
20 anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid
25 [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic
30 carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated
35 amide with imidazole, 4-substituted imidazole,

dimethylpyrazole, triazole or tetrazole; or an activated ester [e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl $[(CH_3)_2N=CH-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (V) to be used.

The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in mixture with water.

In case that the compounds (IV) and (V) are in liquid, they can be used as a solvent.

In this reaction, when the compound (V) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine;

diphenylketene-N-cyclohexylimine, ethoxyacetylene;
1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl
polyphosphate; isopropyl polyphosphate; phosphorus
oxychloride (phosphoryl chloride); phosphorus trichloride;
5 thionyl chloride; oxalyl chloride; lower alkyl haloformate
[e.g. ethyl chloroformate, isopropyl chloroformate, etc.];
triphenylphosphine; 2-ethyl-7-hydroxybenzisoaxasolium salt;
2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide
intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-
10 chloro-1H-benzotriazole; so-called Vilsmeier reagent
prepared by the reaction of N,N-dimethylformamide with
thionyl chloride, phosgene, trichloromethyl chloroformate,
phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence
15 of an inorganic or organic base such as an alkali metal
bicarbonate, alkali metal hydride, tri(lower)alkylamine,
pyridine, N-(lower)alkylmorpholine,
N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the
20 reaction is usually carried out under cooling to heating.

Process (3)

The compound (Ic) or a salt thereof can be prepared
by reacting the compound (VI) or a salt thereof with the
25 compound (VII) or a salt thereof.

The reaction is usually carried out in a conventional
solvent such as chloroform, ether, tetrahydrofuran,
benzene, N,N-dimethylformamide, N,N-dimethylacetamide or
any other organic solvent which does not adversely
30 influence the reaction.

The reaction temperature is not critical and the
reaction is usually carried out under cooling to heating.

The reaction is usually carried out in the presence
of an inorganic or an organic base such as an alkali metal
35 hydroxide, an alkali metal hydrogencarbonate, alkali metal

carbonate, alkali metal hydride (e.g. sodium hydride, etc.), alkali metal acetate, tri(lower)alkylamine, pyridine base (e.g. pyridine, lutidine, picoline, dimethylaminopyridine, etc.), N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like. When the base and/or the starting compound are in liquid, they can be used also as a solvent.

The reaction is preferably carried out in the presence of a dehydrating agent [e.g. Molecular Sieves (trademark : Linde Corporation), etc.].

Process (4)

The compound (Id) or a salt thereof can be prepared by reacting the compound (Ia) or a salt thereof with the compound (VIII).

The reaction is usually carried out in a conventional solvent such as chloroform, ether, tetrahydrofuran, benzene, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

The reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide, an alkali metal hydrogencarbonate, alkali metal carbonate, alkali metal hydride (e.g. sodium hydride, etc.), tri(lower)alkylamine, pyridine base (e.g. pyridine dimethylaminopyridine, etc.) or the like.

When the base and/or the starting compound are in liquid, they can be used also as a solvent.

Process (5)

The compound (Ie) or a salt thereof can be prepared by subjecting the compound (XVI) or a salt thereof to reduction reaction.

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, etc.), copper catalysts (e.g., reduced copper, Raney copper, Ullman copper, etc.) and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, dioxane, N,N-dimethylformamide, or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (6)

The compound (Ig) or a salt thereof can be prepared by subjecting the compound (If) or a salt thereof to elimination reaction of the imino protective group.

5 Suitable method of this elimination reaction may include conventional one such as hydrolysis, reduction and the like.

(i) For Hydrolysis :

10 The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

 Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or
15 hydrogencarbonate thereof, trialkylamine [e.g., trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]-non-5-ene, or the like.

 Suitable acid may include an organic acid [e.g.,
20 formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.].

 The elimination using Lewis acid such as
25 trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like is preferably carried out in the presence of cation trapping agents [e.g., anisole, phenol, etc.].

 The reaction is usually carried out in a conventional
30 solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the
35 reaction.

Among these solvents, hydrophilic solvents may be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

5

(ii) For reduction :

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

10 Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an
15 organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

20 Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium,
25 palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, etc.), copper catalysts (e.g.,
30 reduced copper, Raney copper, Ullman copper, etc.) and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g., methanol,
35 ethanol, propanol, etc.), N,N-dimethylformamide, or a

mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

- 5 The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (7)

- 10 The compound (Ih) or a salt thereof can be prepared by subjecting the compound (XVII) or a salt thereof to reduction reaction.

- 15 This reaction can be carried out in a similar manner to that of the aforementioned Process (5), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (5).

Process (8)

- 20 The compound (Ij) or a salt thereof can be prepared by subjecting the compound (Ii) or a salt thereof to elimination reaction of the hydroxy protective group.

- 25 This reaction can be carried out in a similar manner to that of the aforementioned Process (6), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (6).

Process (9)

- 30 The compound (Ik) or a salt thereof can be prepared by subjecting the compound (Ij) or a salt thereof to oxidation reaction.

- 35 Oxidation is carried out in a conventional manner, and suitable oxidizing agent may be a combination of dimethyl sulfoxide and N,N'-dicyclohexylcarbodiimide, lower alkanolic anhydride (e.g., acetic anhydride, etc.),

phosphorus pentoxide, sulfurtrioxide-pyridine, N-halosuccinimide (e.g., N-chlorosuccinimide, etc.), oxalyl chloride or the like.

5 The reaction may be carried out in the presence of an acid.

 Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, phosphoric
10 acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.] and the like.

 The reaction may be also carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide
15 (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g.,
20 trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g. sodium methoxide, sodium ethoxide, etc.), pyridine (e.g. pyridine, lutidine, picoline, dimethylaminopyridine, etc.),
25 N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like.

 When the base, the acid and/or the starting compound are in liquid, they can be also as a solvent.

 This reaction is usually carried out in a solvent
30 such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction. These conventional solvent
35 may also be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (10)

5 The compound (II) or a salt thereof can be prepared by reacting the compound (XXV) or a salt thereof with the compound (XXXXVI) or a salt thereof.

10 This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.

15 When the starting compound is in liquid, it can be also used as a solvent.

 The reaction is preferably carried out in the presence of the catalyst [e.g., copper halide (e.g., copper (I) chloride, etc.) etc.].

20 The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (A)

25 The compound (IIa) or a salt thereof can be prepared by subjecting the compound (IX) or a salt thereof to cyclization.

 This reaction can be carried out in accordance with the method disclosed in the Preparation 2 described later or a similar manner thereto.

30 Process (B) - (1)

 The compound (XII) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XI) or a salt thereof.

35 This reaction can be carried out in accordance with the method disclosed in the Preparation 3 described later

or a similar manner thereto.

Process (B) - (2)

5 The compound (XIIIIa) or a salt thereof can be prepared by subjecting the compound (XII) or a salt thereof to reduction reaction.

This reaction can be carried out in accordance with the method disclosed in the Preparation 4 described later or a similar manner thereto.

10

Process (C)

The compound (VII) or a salt thereof can be prepared by reacting the compound (XIII) or a salt thereof with the compound (XIV) or a salt thereof.

15 This reaction can be carried out in accordance with the method disclosed in the Preparation 5 described later or a similar manner thereto.

Process (D)

20 The compound (IIc) or a salt thereof can be prepared by subjecting the compound (IIb) or a salt thereof to oxidation reaction.

Oxidation is carried out in a conventional manner, which is capable of oxidizing a sulfur atom to an oxidized sulfur atom, and suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as peroxybenzoic acids (e.g. peroxybenzoic acid, m-chloroperoxybenzoic acid, etc.), and the like.

25
30 The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, chloroform, N,N-dimethylacetamide, N,N-dimethylformamide or any other organic solvent which
35 does not adversely influence the reaction. Among these

solvents, hydrophilic solvents may be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

5

Process (E)

The compound (XVI) or a salt thereof can be prepared by reacting the compound (Im) or a salt thereof with the compound (XV) or a salt thereof.

10 This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not
15 adversely affect the reaction. These conventional solvent may also be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

20 The reaction is usually carried out in the presence of an acid including Lewis acid.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, 25 hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.

When the acid and/or the starting compound are in liquid, they can be also used as a solvent.

30 The reaction is preferably carried out in the presence of a dehydrating agent [e.g. Molecular Sieves, etc.].

Suitable "anion" may include anion derived from the materials used in this reaction such as acid residue [e.g., halogen (e.g. fluorine, chlorine, bromine, iodine), 35 etc.], OH^- and the like.

Process (F)

The compound (IX) or a salt thereof can be prepared by reacting the compound (XVIII) or a salt thereof with the compound (XIX) or its reactive derivative at the carboxy group, or a salt thereof.

Suitable reactive derivative at the carboxy group of the compound (XIX) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; or an activated ester [e.g. ethyl ester, cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl $[(CH_3)_2\overset{+}{N}=CH-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,

N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (XIX) to be used.

5 The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any
10 other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.

 In case that the compounds (XVIII) and (XIX) are in liquid, they can be used as a solvent.

15 In this reaction, when the compound (XIX) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide;
20 N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-
25 cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate
30 [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-
chloro-1H-benzotriazole; so-called Vilsmeier reagent
35 prepared by the reaction of N,N-dimethylformamide with

thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

10 Process (G) - (1)

The compound (XX) or a salt thereof can be prepared by subjecting the compound (IIId) or a salt thereof to reduction reaction.

15 This reaction can be carried out in a similar manner to that of the aforementioned Process (5), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (5).

20 Process (G) - (2)

The compound (XXI) or a salt thereof can be prepared by subjecting the compound (XX) or a salt thereof to oxidation reaction.

25 This reaction can be carried out in a similar manner to that of the aforementioned Process (9), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (9).

30 Process (H)

The compound (XXIII) or a salt thereof can be prepared by reacting the compound (XXIa) or a salt thereof with the compound (XXII) or a salt thereof.

35 This reaction can be carried out in the manner

disclosed in Preparation 11-(1) or similar manners thereto.

Process (I)

5 The compound (XXVa) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the carboxy group, or a salt thereof with the compound (XXIV) or its reactive derivative at the amino group, or a salt thereof.

10 This reaction can be carried out in a similar manner to that of the aforementioned Process (1), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (1).

15

Process (J)

 The compound (XVIIa) or a salt thereof can be prepared by reacting the compound (In) or a salt thereof with the compound (XXVI) or a salt thereof.

20 This reaction can be carried out in the manner disclosed in Preparation 13-(1) or similar manners thereto.

Process (K)

25 The compound (IIe) or a salt thereof can be prepared by reacting the compound (XXVII) or a salt thereof with the compound (XXVIII) or a salt thereof.

 This reaction can be carried out in the manner disclosed in Preparation 14 or similar manners thereto.

30

Process (L) - (1)

 The compound (XXXI) can be prepared by reacting the compound (XXIX) or a salt thereof with the compound (XXX) or a salt thereof.

35 This reaction can be carried out in the manner

disclosed in Preparations 17-(1) and 20 or similar manners thereto.

Process (L) - ②

The compound (XXXIIIIa) or a salt thereof can be prepared by reacting the compound (XXXI) with the compound (XXXII) or a salt thereof.

This reaction can be carried out in the manner disclosed in Preparations 18-(1) and 21 or similar manners thereto.

Process (M)

The compound (XXXIIIc) or a salt thereof can be presented by reacting the compound (XXXIIIb) or a salt thereof with the compound (XXXIV) or a salt thereof and then by subjecting the resultant compound to reduction reaction.

This reaction can be carried out in the manner disclosed in Preparation 19-(1) or similar manners thereto.

Process (N)

The compound (XXXIIId) or a salt thereof can be prepared by subjecting the compound (XXXIIb) or a salt thereof to acylation reaction.

Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula :



(wherein R_a^2 is C_1 - C_5 alkanoyl, aroyl which may have suitable substituent(s), or ar(C_1 - C_5)alkanoyl which may have suitable substituent(s).)

or its reactive derivative or a salt thereof.

Suitable reactive derivative of the compound (XXXXVII) may include an acid halide, an acid anhydride, an activated amide, an activated ester, isocyanate, and the like. The suitable example may be an acid chloride, an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g. methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid or trichloroacetic acid, etc.) or aromatic carboxylic acid (e.g. benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; or an activated ester (e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl $[(CH_3)_2N^+=CH-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.), or an ester with a N-hydroxy compound (e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridine, N-hydroxysuccinimide, N-hydroxybenzotriazole, N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.); substituted or unsubstituted aryl isocyanate; substituted or unsubstituted aryl isothiocyanate, and the like. These reactive derivatives can optionally be

selected from them according to the kind of the compound (XXXXVII) to be used.

5 The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely influence the reaction. These conventional solvents may also be used in a mixture with water.

10 When the compound (XXXXVII) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; 15 N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine; 20 ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; triphoenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide 25 intra-molecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, phosphorus oxychloride, etc.; 30 or the like.

The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, 35 or the like. The reaction temperature is not critical,

and the reaction is usually carried out under cooling to heating.

Process (O)

5 The compound (XXXIIIe) or a salt thereof can be prepared by subjecting the compound (XXXIIId) or a salt thereof to reduction reaction.

 This reaction can be carried out in a similar manner to that of the aforementioned Process (5), and therefore
10 the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (5).

Process (P)

15 The compound (XXXVII) or a salt thereof can be prepared by reacting the compound (XXXV) or a salt thereof with the compound (XXXVI).

 This reaction can be carried out in the manner disclosed in Preparation 24 or similar manners thereto.

20

Process (Q) - (1)

 The compound (XXXVIIIa) or a salt thereof can be prepared by subjecting the compound (XXXVII) or a salt thereof to reduction reaction.

25 This reaction can be carried out in the manner disclosed in Preparation 25 or similar manners thereto.

Process (Q) - (2)

30 The compound (XXXIX) or a salt thereof can be prepared by subjecting the compound (XXXVIII) or a salt thereof to reduction reaction.

 This reaction can be carried out in the manner disclosed in Preparation 26 or similar manners thereto.

35

Process (R) - (1)

The compound (XXXXII) or a salt thereof can be prepared by reacting the compound (XXXX) or a salt thereof with the compound (XXXXI) or a salt thereof.

5 This reaction can be carried out in the manner disclosed in Preparation 27 or similar manners thereto.

Process (R) - (2)

10 The compound (XXXIX) or a salt thereof can be prepared by subjecting the compound (XXXXII) or a salt thereof to reduction reaction.

This reaction can be carried out in a similar manner to that of the aforementioned Process (5), and therefore the reagents to be used and the reaction conditions (e.g.,
15 solvent, reaction temperature, etc.) can be referred to those of the Process (5).

Process (S) - (1)

20 The compound (VII) or a salt thereof can be prepared by reacting the compound (XXXXIII) or a salt thereof with the compound (XIV) or a salt thereof.

This reaction can be carried out in the manner disclosed in Preparation 29 or similar manners thereto.

Process (S) - (2)

25 The compound (XXXXIV) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (XIX) or its reactive derivative at the carboxy group, or a salt thereof.

30 This reaction can be carried out in a similar manner to that of the aforementioned Process (F), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (F).

Process (T)

The compound (IIIf) or a salt thereof can be prepared by subjecting the compound (XXXV) or a salt thereof to cyclization reaction.


5 This reaction can be carried out in the manner disclosed in Preparation 31-(1) or similar manners thereto.

Suitable salts of the object and starting compounds and their reactive derivatives in Processes (1)~(10) and 10 (A)~(T) can be referred to the ones as exemplified for the compound (I).

Preferred embodiments of the object compound (I) are as follows.

15

R^1 is lower alkyl, a heterocyclic group which may have 1 to 3 suitable substituent(s) [more preferably unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), 20 unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) or saturated heterobicyclic group of the formula :



each of which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower 30 alkenyl, lower alkynyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, cyano, nitro, mono(or di or tri)halo(lower)alkyl and acyl; most preferably pyridyl, thienyl or quinuclidinyl, 35 each of which may have cyano],


aryl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano and acyl [more preferably phenyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano, lower alkylsulfonyl and lower alkanoyl; most preferably phenyl which may have a substituent selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano, lower alkylsulfonyl and lower alkanoyl], ar(lower)alkyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl [more preferably phenyl(lower)alkyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl; most preferably phenyl(lower)alkyl which may have nitro], or ar(lower)alkenyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl [more preferably phenyl(lower)alkenyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower

- 60 -

alkylsulfinyl and lower alkylsulfonyl; most preferably phenyl(lower)alkenyl which may have cyano or nitro],

Q is oxadiazolediyl (more preferably

5




10 Z is bond or vinyl,

X is bond,

a group of the formula :

15



(in which R^4 is hydrogen or lower alkyl),
a group of the formula :


20



25

(in which R^8 is hydroxy or protected hydroxy [more preferably acyloxy, most preferably lower alkanoyloxy]),

30



A is bond, lower alkylene or lower alkynylene,

M is unsaturated 5 or 6-membered heteromonocyclic group
containing 1 to 4-nitrogen atom(s) or

35

5 saturated 5 or 6-membered heteromonocyclic group
containing 1 to 4 nitrogen atom(s), each of which may
have one substituent selected from the group
consisting of lower alkyl, an imino protective group
and ar(lower)alkyl which may have 1 to 3 suitable
substituent(s) [more preferably piperidyl,
10 piperazinyl, pyrrolidinyl, tetrahydropyridyl or
pyridyl, each of which may have one substituent
selected from the group consisting of lower alkyl,
acyl and phenyl(lower)alkyl which may have 1 to 2
substituent(s) selected from the group consisting of
halogen, cyano, nitro, lower alkyl, lower alkoxy and
lower alkylthio;
15 most preferably piperidyl, piperazinyl, pyrrolidinyl,
tetrahydropyridyl or pyridyl, each of which may have
one substituent selected from the group consisting of
lower alkyl, lower alkoxy carbonyl and
phenyl(lower)alkyl which may have a substituent
selected from the group consisting of halogen, cyano,
20 nitro, lower alkyl and lower alkoxy].

The object compound (I) of this invention and
pharmaceutically acceptable salts thereof possess strong
inhibitory activity against acetylcholinesterase, but
25 hardly possess inhibitory activity against
butyrylcholinesterase. That is, the object compound (I)
of this invention and pharmaceutically acceptable salts
thereof are selective inhibitors of acetylcholinesterase
and muscarinic agonist and therefore useful for the
30 treatment of disorders in the central nervous system such
as amnesia, dementia [e.g., senile dementia of Alzheimer
type, vascular dementia, etc.], cerebrovascular disease or
the like.

In order to illustrate the usefulness of the object
35 compound (I), the pharmacological test data of the

compound (I) are shown in the following.

[1] Test Compound

5 (a) 5-(Quinuclidin-3-yl)-3-[[2-(1-benzylpiperidin-4-yl)-ethyl]carbamoyl]-1,2,4-oxadiazole dihydrochloride

(b) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

10

[2] Inhibition of acetylcholinesterase

(i) Test Method :

15 The ability to inhibit acetylcholinesterase was determined by the method (enzyme assay) described in Clinica Chimica Acta, 115 (1981) 163-170.

The acetylcholinesterase used in this test was obtained from rat's corpus striatum.

20 [3] Test Result :

	Test compound	IC ₅₀ (M)
25	(a)	8.0 x 10 ⁻⁹
	(b)	1.7 x 10 ⁻⁹

30 The object compound (I) or its pharmaceutically acceptable salts can usually be administered to mammals including human being in the form of a conventional pharmaceutical composition such as capsule, micro-capsule, tablet, granule, powder, troche, syrup, aerosol,
35 inhalation, solution, injection, suspension, emulsion, or

the like.

The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g. sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc.), binding agent (cellulose, methylcellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.), disintegrator (e.g. starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycole-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.), lubricant (e.g. magnesium stearate, talc, sodium laurylsulfate, etc.), flavoring agent (e.g. citric acid, menthol, glycine, orange powders, etc.), preservative (e.g. sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.), stabilizer (e.g. citric acid, sodium citrate, acetic acid, etc.), suspending agent (e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent, aqueous diluting agent (e.g. water), base wax (e.g. cacao butter, polyethyleneglycol, white petrolatum, etc.).

The effective ingredient may usually be administered with a unit dose of 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight, conditions of the patient or the administering method.

The following Examples and Preparations are given for the purpose of illustrating the present invention in more detail.

Preparation 1

- (1) To a solution of 4-nitrobenzoyl chloride (10 g) in tetrahydrofuran (150 ml) was added a suspension of ethyl 2-amino-2-hydroxyiminoacetate (7.1 g) in tetrahydrofuran (30 ml). After stirring for 2 hours, the precipitates were collected by filtration and washed with diethyl ether to afford ethyl 2-amino-2-(4-nitrobenzoyloxyimino)acetate (12.19 g).

mp : 192-194°C

10 IR (Nujol) : 3425, 3325, 1740, 1710 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.31 (3H, t, $J=7\text{Hz}$), 4.32 (2H, q, $J=7\text{Hz}$), 7.3-7.5 (2H, br s), 8.33 (2H, d, $J=9\text{Hz}$), 8.45 (2H, d, $J=9\text{Hz}$)

- 15 The following compounds were obtained according to a similar manner to that of Preparation 1-(1).

- (2) Ethyl 2-amino-2-(4-methoxybenzoyloxyimino)acetate

mp : 171-172°C

20 IR (Nujol) : 3475, 3360, 1725, 1080 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 3.86 (3H, s), 4.30 (2H, q, $J=7.1\text{Hz}$), 7.04 (2H, d, $J=9\text{Hz}$), 7.14 (2H, br s), 8.16 (2H, d, $J=9\text{Hz}$)

- 25 (3) Ethyl 2-amino-2-nicotinoyloxyiminoacetate

mp : 178-179°C

IR (Nujol) : 3420, 3260, 1730, 1640, 1590 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 4.32 (2H, q, $J=7.1\text{Hz}$), 7.31 (2H, s), 7.59 (1H, ddd, $J=0.8, 4.9, 8.0\text{Hz}$), 8.55 (1H, ddd, $J=2.0, 2.0, 8.0\text{Hz}$), 8.84 (1H, dd, $J=2.0, 4.9\text{Hz}$), 9.34 (1H, dd, $J=0.8, 2.0\text{Hz}$)

Mass (m/z) : 237 (M^+)

- 35 (4) Ethyl 2-amino-2-(4-trifluoromethylbenzoyloxyimino)-acetate

mp : 205-206°C

IR (Nujol) : 3420, 3330, 1740, 1720, 1630, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 4.32 (2H, q, $J=7.1\text{Hz}$), 7.32 (2H, br), 7.90 (2H, d, $J=8.3\text{Hz}$), 8.41 (2H, d, $J=8.3\text{Hz}$)

Mass (m/z) : 304 (M^+)

Preparation 2

(1) A suspension of ethyl 2-amino-2-(4-nitrobenzoyloxy-imino)acetate (2.8 g) and powdered molecular sieves 3A (5 g) was refluxed for 24 hours. After evaporating the solvent, the residue was subjected to column chromatography on silica gel (200 ml) with methylene chloride-n-hexane as eluent. The fractions containing the object compound were combined and evaporated in vacuo to afford 3-ethoxycarbonyl-5-(4-nitrophenyl)-1,2,4-oxadiazole (1.8 g).

mp : 75-77°C

IR (Nujol) : 1750, 1605, 1210 cm^{-1}

NMR (CDCl_3 , δ) : 1.49 (3H, t, $J=7.1\text{Hz}$), 4.57 (2H, q, $J=7.1\text{Hz}$), 8.44 (4H, s)

The following compounds were obtained according to a similar manner to that of Preparation 2-(1).

(2) 3-Ethoxycarbonyl-5-(4-methoxyphenyl)-1,2,4-oxadiazole

mp : 75-77°C

IR (Nujol) : 1750, 1605, 1210 cm^{-1}

NMR (CDCl_3 , δ) : 1.47 (3H, t, $J=7.1\text{Hz}$), 3.90 (3H, s), 4.54 (2H, q, $J=7.1\text{Hz}$), 7.03 (2H, d, $J=9\text{Hz}$), 8.16 (2H, d, $J=9\text{Hz}$)

(3) 3-Ethoxycarbonyl-5-(3-nitrophenyl)-1,2,4-oxadiazole

mp : 75-77°C

IR (Nujol) : 1730, 1620, 900, 720 cm^{-1}

NMR (CDCl_3 , δ) : 1.50 (3H, t, $J=7.1\text{Hz}$), 4.58 (2H, q, $J=7.1\text{Hz}$), 7.8-7.9 (1H, m), 8.5-8.6 (2H, m), 7.07-9.07 (1H, m)

5 (4) 3-Ethoxycarbonyl-5-(4-methylthiophenyl)-1,2,4-oxadiazole

mp : 82-83°C

IR (Nujol) : 1745, 1595, 1200, 740 cm^{-1}

10 NMR (CDCl_3 , δ) : 1.47 (3H, t, $J=7.1\text{Hz}$), 2.55 (3H, s), 4.55 (2H, q, $J=7.1\text{Hz}$), 7.35 (2H, d, $J=8.6\text{Hz}$), 8.09 (2H, d, $J=8.6\text{Hz}$)

Mass (m/z) : 264 (M^+)

15 (5) 3-Ethoxycarbonyl-5-(pyridin-3-yl)-1,2,4-oxadiazole

mp : 45-46°C

IR (Nujol) : 1740, 1600, 1580 cm^{-1}

20 NMR (CDCl_3 , δ) : 1.49 (3H, t, $J=7.1\text{Hz}$), 4.57 (2H, q, $J=7.1\text{Hz}$), 7.55 (1H, ddd, $J=0.6, 4.9, 7.9\text{Hz}$), 8.50 (1H, ddd, $J=1.6, 1.6, 8.0\text{Hz}$), 8.88 (1H, dd, $J=1.6, 4.9\text{Hz}$), 9.45 (1H, dd, $J=0.8, 1.6\text{Hz}$)

Mass (m/z) : 219 (M^+)

25 (6) 3-Ethoxycarbonyl-5-(4-trifluoromethylphenyl)-1,2,4-oxadiazole

mp : 104-105°C

IR (Nujol) : 3330, 3100, 1750, 1640, 1590 cm^{-1}

30 NMR ($\text{DMSO}-d_6$, δ) : 1.38 (3H, t, $J=7.1\text{Hz}$), 4.47 (2H, q, $J=7.1\text{Hz}$), 7.89 (2H, d, $J=8.3\text{Hz}$), 8.37 (2H, d, $J=8.3\text{Hz}$)

Mass (m/z) : 286 (M^+)

Preparation 3

To a suspension of 4-cyanobutyltriphenylphosphonium bromide (21.80 g) in tetrahydrofuran (100 ml) was added
35 potassium tert-butoxide (5.76 g) in tetrahydrofuran (50

ml) over 30 minutes at 0°C. After 1 hour, a solution of 1-benzyl-4-piperidone (8.84 g) was added to the mixture over 30 minutes at 0°C. The mixture was stirred at ambient temperature for 1 hour, poured into ice-water and
5 extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on alumina eluting with chloroform/hexane (1:1) and the fractions containing the object compound were combined and evaporated to afford
10 1-benzyl-4-(4-cyanobutylidene)piperidine (9.8 g) as an oil.

IR (Film) : 2250, 1600, 1495 cm^{-1}

NMR (CDCl_3 , δ) : 1.65-1.76 (2H, m), 2.10-2.48 (12H, m), 3.51 (2H, s), 5.05 (1H, t, $J=7.2\text{Hz}$),
15 7.21-7.36 (5H, m)

Mass (m/z) : 254 (M^+)

Preparation 4

A mixture of 1-benzyl-4-(4-cyanobutylidene)piperidine
20 (8.8 g) and platinum dioxide (1.2 g) in tetrahydrofuran (150 ml) was hydrogenated at atmospheric pressure for 12 hours. After the catalyst was filtered out, the filtrate was evaporated in vacuo. The residue was chromatographed on silica gel eluting with chloroform/methanol (95:5) and
25 the fractions containing the object compound were combined and evaporated to afford 1-benzyl-4-(4-cyanobutyl)-piperidine (5.0 g) as an oil.

IR (Film) : 2250, 1600, 1490 cm^{-1}

NMR (CDCl_3 , δ) : 1.23-1.27 (5H, m), 1.41-1.45 (2H, m), 1.52-1.71 (4H, m), 1.86-1.96 (2H, m), 2.33
30 (2H, t, $J=6.8\text{Hz}$), 2.84-2.90 (2H, m), 3.48 (2H, s), 7.21-7.32 (5H, m)

Mass (m/z) : 255 (M^+)

Preparation 5

A mixture of 1-benzyl-4-(4-cyanobutyl)piperidine (2.20 g), potassium carbonate (3.56 g) and hydroxylamine hydrochloride (2.39 g) was heated under reflux for 20 hours. After cooling, the mixture was filtered and evaporated in vacuo. The residue was dissolved in ether, filtered and recrystallized to afford 5-(1-benzylpiperidin-4-yl)-1-hydroxyiminopentylamine (1.56 g).
mp : 82-85°C
10 IR (Nujol) : 3500, 3480, 3150, 1670, 1640, 1595 cm^{-1}
NMR (CDCl_3 , δ) : 1.08-1.15 (7H, m), 1.45-1.64 (4H, m), 1.90 (2H, t, $J=10.0\text{Hz}$), 2.11 (2H, t, $J=7.9\text{Hz}$), 2.85 (2H, d, $J=10.8\text{Hz}$), 3.48 (2H, s), 4.52 (2H, s), 7.21-7.31 (5H, s)
15 Mass (m/z) : 273 (M^+)

Preparation 6

The following compounds were obtained according to a similar manner to that of Preparation 1-(1).

- 20 (1) Ethyl 2-amino-2-(2-nitrobenzoyloxyimino)acetate
mp : 176-177°C
NMR ($\text{DMSO}-d_6$, δ) : 1.29 (3H, t, $J=7.1\text{Hz}$), 4.28 (2H, q, $J=7.1\text{Hz}$), 7.16-7.20 (2H, br), 7.78-8.00 (3H, m), 8.09-8.17 (1H, m)
25 Mass (m/z) : 282 (M^++1)
- (2) Ethyl 2-amino-2-(4-chlorobenzoyloxyimino)acetate
NMR ($\text{DMSO}-d_6$, δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 4.31 (2H, q, $J=7.1\text{Hz}$), 7.24-7.28 (2H, br), 7.60 (2H, d, $J=8.6\text{Hz}$), 8.22 (2H, d, $J=8.6\text{Hz}$)
30
- (3) Ethyl 2-amino-2-(4-pyridylcarbonyloxyimino)acetate
mp : 163-165°C
35 IR (Nujol) : 3420, 3320, 1740, 1620 cm^{-1}

NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.1Hz), 4.32 (2H, q, J=7.1Hz), 7.30-7.35 (2H, br), 8.10 (2H, d, J=6.1Hz), 8.80 (2H, d, J=6.1Hz)

5 (4) Ethyl 2-amino-2-acetoxyiminoacetate

mp : 161-162°C

IR (Nujol) : 3410, 3300, 1750, 1620 cm⁻¹

NMR (DMSO-d₆, δ) : 1.27 (3H, t, J=7.1Hz), 2.11 (3H, s), 4.26 (2H, q, J=7.1Hz), 6.97-7.01 (2H, br)

10 Mass (m/z) : 174 (M⁺)

(5) 5-(1-Benzylpiperidin-4-yl)-1-(4-nitrobenzoyloxy-imino)pentylamine

mp : 110-112°C

15 IR (Film) : 3500, 3330, 1730, 1640, 1600 cm⁻¹

NMR (CDCl₃, δ) : 1.25-1.35 (7H, m), 1.57-1.68 (4H, m), 1.92-2.03 (2H, m), 2.31-2.38 (2H, m), 2.89-2.95 (2H, m), 4.84-4.88 (2H, br), 7.27-7.34 (5H, m), 8.20 (2H, d, J=9.0Hz), 8.29 (2H, d, J=9.0Hz)

20

Elemental Analysis Calcd. for C₂₄H₃₀N₄O₄ :

C 65.73, H 6.89, N 12.77

Found : C 65.58, H 7.05, N 12.65

25 Preparation 7

The following compounds were obtained according to a similar manner to that of Preparation 2-(1).

(1) 3-Ethoxycarbonyl-5-(4-cyanophenyl)-1,2,4-oxadiazole

30 mp : 127-129°C

IR (Nujol) : 2220, 1740 cm⁻¹

(2) 3-Ethoxycarbonyl-5-(2-nitrophenyl)-1,2,4-oxadiazole

mp : 176-178°C

35 IR (Nujol) : 1750 cm⁻¹

NMR (DMSO- d_6 , δ) : 1.37 (3H, t, $J=7.1\text{Hz}$), 4.47 (2H, q, $J=7.1\text{Hz}$), 7.98-8.07 (2H, m), 8.11-8.18 (1H, m), 8.26-8.35 (1H, m)

Mass (m/z) : 263 (M^+)

5

(3) 3-Ethoxycarbonyl-5-(4-chlorophenyl)-1,2,4-oxadiazole

mp : 92-94°C

IR (Nujol) : 1740, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.40 (3H, t, $J=7.1\text{Hz}$), 4.45 (2H, q, $J=7.1\text{Hz}$), 7.73 (2H, d, $J=8.6\text{Hz}$), 8.16 (2H, d, $J=8.6\text{Hz}$)

10

Mass (m/z) : 252 (M^+)

(4) 3-Ethoxycarbonyl-5-(4-pyridyl)-1,2,4-oxadiazole

15

mp : 65-67°C

IR (Nujol) : 3500, 3400, 1730 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.39 (3H, t, $J=7.1\text{Hz}$), 4.47 (2H, q, $J=7.1\text{Hz}$), 8.08 (2H, d, $J=6.1\text{Hz}$), 8.91 (2H, d, $J=6.1\text{Hz}$)

20

(5) 3-Ethoxycarbonyl-5-(4-fluorophenyl)-1,2,4-oxadiazole

mp : 64-65°C

IR (Nujol) : 1740, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 1.48 (3H, t, $J=7.1\text{Hz}$), 4.55 (2H, q, $J=7.1\text{Hz}$), 7.20-7.31 (2H, m), 8.20-8.30 (2H, m)

25

Mass (m/z) : 236 (M^+)

(6) 3-Ethoxycarbonyl-5-methyl-1,2,4-oxadiazole

mp : 31-32°C

IR (Nujol) : 1740 cm^{-1}

NMR (CDCl_3 , δ) : 1.45 (3H, t, $J=7.2\text{Hz}$), 2.70 (3H, s), 4.51 (2H, q, $J=7.2\text{Hz}$)

30

(7) 3-Ethoxycarbonyl-5-(2-cyanothiophen-5-yl)-1,2,4-oxadiazole

35

- mp : 118-120°C
IR (Nujol) : 2220, 1740, 1600 cm^{-1}
NMR (CDCl_3 , δ) : 1.48 (3H, t, $J=7.1\text{Hz}$), 4.55 (2H, q, $J=7.1\text{Hz}$), 7.72 (1H, d, $J=4.1\text{Hz}$), 7.99 (1H, d, $J=4.1\text{Hz}$)
- 5
- (8) 3-Ethoxycarbonyl-5-((E)-2-(4-nitrophenyl)vinyl)-1,2,4-oxadiazole
mp : 187-188°C
10 IR (Nujol) : 1735, 1640, 1210, 840 cm^{-1}
NMR ($\text{DMSO}-d_6$, δ) : 1.35 (3H, t, $J=7.1\text{Hz}$), 4.43 (2H, q, $J=7.1\text{Hz}$), 7.71 (2H, d, $J=16.5\text{Hz}$), 8.13 (2H, d, $J=16.5\text{Hz}$), 8.13 (2H, d, $J=8.8\text{Hz}$), 8.30 (2H, d, $J=8.8\text{Hz}$)
- 15
- (9) 3-Ethoxycarbonyl-5-(4-acetylphenyl)-1,2,4-oxadiazole
mp : 100-101°C
IR (Nujol) : 1740, 1680, 1220 cm^{-1}
NMR ($\text{DMSO}-d_6$, δ) : 1.37 (3H, t, $J=7.1\text{Hz}$), 2.67 (3H, s), 4.46 (2H, q, $J=7.1\text{Hz}$), 8.18 (2H, d, $J=8.4\text{Hz}$), 8.30 (2H, d, $J=8.4\text{Hz}$)
- 20
- (10) 3-Ethoxycarbonyl-5-((E)-2-(4-cyanophenyl)vinyl)-1,2,4-oxadiazole
mp : 159-160°C
25 IR (Nujol) : 2225, 1735, 1630, 1220 cm^{-1}
NMR ($\text{DMSO}-d_6$, δ) : 1.35 (3H, t, $J=7.1\text{Hz}$), 4.43 (2H, q, $J=7.1\text{Hz}$), 7.67 (2H, d, $J=16.5\text{Hz}$), 7.95 (2H, d, $J=8.4\text{Hz}$), 8.06 (2H, d, $J=16.5\text{Hz}$), 8.07 (2H, d, $J=8.4\text{Hz}$)
- 30
- (11) 3-Ethoxycarbonyl-5-(4-nitrobenzyl)-1,2,4-oxadiazole
mp : 120-121°C
IR (Nujol) : 1740, 1350, 725 cm^{-1}
35 NMR ($\text{DMSO}-d_6$, δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 4.39 (2H,

q, $J=7.1\text{Hz}$), 4.68 (2H, s), 7.68 (2H, d, $J=9.3\text{Hz}$), 8.25 (2H, d, $J=9.3\text{Hz}$)

Preparation 8

5 (1) To a mixture of 4-fluorobenzoic acid (2.0 g), ethyl 2-amino-2-hydroxyiminoacetate (2.07 g) and 4-dimethylaminopyridine (0.52 g) in methylene chloride (30 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (2.87 ml) at 0°C under stirring. After
10 stirring at ambient temperature for 1 hour, diethyl ether (10 ml) was added thereto and the resulting precipitate was filtered off, washed with diethyl ether, and dried in vacuo to give ethyl 2-amino-2-(4-fluorobenzoyloxyimino)-acetate (3.2 g).

15 mp : 196-198°C

IR (Nujol) : 3400, 3300, 1740, 1620 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.31 (3H, t, $J=7.1\text{Hz}$), 4.31 (2H, q, $J=7.1\text{Hz}$), 7.23-7.25 (2H, br), 7.31-7.41 (2H, m), 8.25-8.33 (2H, m)

20 Mass (m/z) : 254 (M^+)

The following compound was obtained according to a similar manner to that of Preparation 8-(1).

25 (2) Ethyl 2-amino-2-[(2-cyanothiophen-5-yl)carbonyloxyimino]acetate

mp : 196-197°C

IR (Nujol) : 3420, 3320, 2220, 1730, 1620 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.30 (3H, t, $J=7.1\text{Hz}$), 4.31 (2H, q, $J=7.1\text{Hz}$), 7.34-7.40 (2H, br), 8.10 (1H, d, $J=4.0\text{Hz}$), 8.32 (1H, d, $J=4.0\text{Hz}$)

Mass (m/z) : 267 (M^+)

Preparation 9

35 (1) To a solution of 5-(4-cyanophenyl)-3-ethoxycarbonyl-

1,2,4-oxadiazole (5.0 g) in methanol (50 ml) -
tetrahydrofuran (50 ml) was added sodium borohydride (0.93
g) at 0°C. After stirring at 5-10°C for 1 hour, the
mixture was poured into water and extracted with ethyl
acetate. The extract was washed with water and brine,
dried over magnesium sulfate, and evaporated in vacuo.
The residue was recrystallized from diethyl ether to give
5-(4-cyanophenyl)-3-hydroxymethyl-1,2,4-oxadiazole (4.0
g).

mp : 138-140°C
IR (Nujol) : 3330, 2220 cm^{-1}
NMR (DMSO- d_6 , δ) : 4.65 (2H, d, $J=6.1\text{Hz}$), 5.84 (1H,
t, $J=6.1\text{Hz}$), 8.11 (2H, d, $J=8.2\text{Hz}$), 8.29 (2H, d,
 $J=8.2\text{Hz}$)

15

The following compound was obtained according to a
similar manner to that of Preparation 9-(1).

(2) 3-Hydroxymethyl-5-(4-nitrophenyl)-1,2,4-oxadiazole
mp : 155-156°C
IR (Nujol) : 3350, 1600 cm^{-1}
NMR (DMSO- d_6 , δ) : 4.68 (2H, d, $J=6.0\text{Hz}$), 5.85 (1H,
t, $J=6.0\text{Hz}$), 8.35 (2H, d, $J=9.1\text{Hz}$), 8.44 (2H, d,
 $J=9.1\text{Hz}$)
Mass (m/z) : 220 (M^+ of free compound - 1)

25

Preparation 10

(1) A mixture of 5-(4-cyanophenyl)-3-hydroxymethyl-1,2,4-
oxadiazole (4.08 g), N,N'-dicyclohexylcarbodiimide (20.92
g) and o-phosphoric acid (9.94 g) in dimethyl sulfoxide
(80 ml) was stirred at ambient temperature. After 1 hour,
the mixture was poured into water and extracted with ethyl
acetate. The extract was washed with water and brine,
dried over magnesium sulfate, and evaporated in vacuo.
The residue was recrystallized from ether to give

35

5-(4-cyanophenyl)-3-formyl-1,2,4-oxadiazole (2.17 g).

mp : 168-170°C (dec.)

IR (Nujol) : 3320, 2230, 1715 cm^{-1}

NMR (DMSO- d_6 , δ) : 8.11 (2H, d, $J=8.5\text{Hz}$), 8.28 (2H, d, $J=8.5\text{Hz}$)

5

The following compound was obtained according to a similar manner to that of Preparation 10-(1).

10 (2) 3-Formyl-5-(4-nitrophenyl)-1,2,4-oxadiazole

mp : 169-171°C (dec.)

IR (Nujol) : 1710 cm^{-1}

NMR (DMSO- d_6 , δ) : 8.37 (2H, d, $J=9.1\text{Hz}$), 8.45 (2H, d, $J=9.1\text{Hz}$)

15

Preparation 11

(1) A mixture of 5-(4-cyanophenyl)-3-formyl-1,2,4-oxadiazole (2.0 g), malonic acid (4.18 g) and piperidine (0.50 ml) in pyridine (20 ml) was refluxed for 1 hour.

20 After cooling to room temperature, the mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate, acidified to pH 2.0 with 4N hydrochloric acid washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was recrystallized from ethanol to give 3-{{E}-2-carboxyvinyl}-5-(4-cyanophenyl)-1,2,4-oxadiazole (1.2 g).

25

mp : 222-225°C (dec.)

IR (Nujol) : 2230, 1690 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 6.92 (1H, d, $J=15.8\text{Hz}$), 7.51 (1H, d, $J=15.8\text{Hz}$), 8.13 (2H, d, $J=8.6\text{Hz}$), 8.30 (2H, d, $J=8.6\text{Hz}$)

The following compound was obtained according to a similar manner to that of Preparation 11-(1).

35

(2) 3-{{(E)-2-Carboxyvinyl}-5-(4-nitrophenyl)-1,2,4-oxadiazole

mp : 206-208°C (dec.)

IR (Nujol) : 1690 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 6.93 (1H, d, $J=15.8\text{Hz}$), 7.53 (1H, d, $J=15.8\text{Hz}$), 8.38-8.49 (4H, m)

Preparation 12

10 The following compound was obtained according to a similar manner to that of Example 1.

3-{{(2-Propynyl)carbamoyl}-5-(4-nitrophenyl)-1,2,4-oxadiazole

mp : 188-189°C (dec.)

15 IR (Nujol) : 3330, 3250, 1680 cm^{-1}

NMR (DMSO- d_6 , δ) : 3.20 (1H, t, $J=2.5\text{Hz}$), 4.08 (2H, d, $J=2.5\text{Hz}$), 8.40 (2H, d, $J=9.1\text{Hz}$), 8.49 (2H, d, $J=9.1\text{Hz}$), 9.60-9.64 (1H, br)

Mass (m/z) : 272 (M^+)

20 Elemental Analysis Calcd. for $\text{C}_{12}\text{H}_8\text{N}_4\text{O}_4$:

C 52.94, H 2.96, N 20.58

Found : C 52.85, H 2.76, N 20.29

Preparation 13

25 (1) A mixture of 3-[[2-(pyridin-4-yl)ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole (0.72 g) and 4-fluorobenzyl iodide (0.80 g) in dimethyl sulfoxide (5 ml) was stirred at 50°C for 1 hour. After cooling to room temperature, the mixture was evaporated in vacuo. The
30 residue was recrystallized from diethyl ether to give 3-[[2-{1-(4-fluorobenzyl)-4-pyridinio}ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole iodide (1.0 g).

mp : 202-204°C

IR (Nujol) : 3200, 2230, 1680 cm^{-1}

35 NMR (DMSO- d_6 , δ) : 3.21-3.24 (2H, m), 3.70-3.73 (2H,

m), 5.79 (2H, s), 7.29 (2H, dd, J=8.8, 8.8Hz),
7.60 (2H, dd, J=5.4, 8.8Hz), 8.10 (2H, d,
J=6.7Hz), 8.15 (2H, d, J=8.6Hz), 8.30 (2H, d,
J=8.6Hz), 9.09 (2H, d, J=6.7Hz), 9.26-9.30 (1H,
m)

Mass (m/z) : 428 ($M^+ - I^-$)

The following compounds were obtained according to a
similar manner to that of Preparation 13-(1).

10

(2) 3-[[2-(1-Benzyl-4-pyridinio)ethyl]carbamoyl]-5-(4-
cyanophenyl)-1,2,4-oxadiazole iodide

mp : 208-209°C

IR (Nujol) : 3180, 2230, 1680, 1635 cm^{-1}

15

NMR (DMSO- d_6 , δ) : 3.18-3.25 (2H, m), 3.68-3.74 (2H,
m), 5.82 (2H, s), 7.41-7.51 (5H, m), 8.10 (2H,
d, J=6.6Hz), 8.15 (2H, d, J=8.5Hz), 8.30 (2H, d,
J=8.5Hz), 9.11 (2H, d, J=6.6Hz), 9.25-9.31 (1H,
m)

20

Elemental Analysis Calcd. for $C_{24}H_{20}IN_5O_2$:

C 53.64, H 3.75, N 13.03

Found : C 53.57, H 3.67, N 12.95

25

(3) 3-[[2-(1-Benzyl-4-pyridinio)ethyl]carbamoyl]-5-(4-
nitrophenyl)-1,2,4-oxadiazole iodide

mp : 207-208°C

IR (Nujol) : 3200, 1680, 1630 cm^{-1}

30

NMR (DMSO- d_6 , δ) : 3.20-3.25 (2H, m), 3.70-3.75 (2H,
m), 5.81 (2H, s), 7.41-7.48 (5H, m), 8.10 (2H,
d, J=6.5Hz), 8.39 (2H, d, J=9.0Hz), 8.49 (2H, d,
J=9.0Hz), 9.10 (2H, d, J=6.5Hz), 9.30-9.34 (1H,
m)

Mass (m/z) : 430 ($M^+ - I^-$)

35

(4) 3-[[2-{1-(4-Fluorobenzyl)-4-pyridinio}ethyl]-

carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole iodide

mp : 198-200°C

IR (Nujol) : 3500, 3410, 3300, 1680, 1630, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 3.23 (2H, t, $J=6.5\text{Hz}$), 3.71-3.75

5 (2H, m), 5.82 (2H, s), 7.30 (2H, dd, $J=8.8$,
8.8Hz), 7.62 (2H, dd, $J=5.4$, 8.8Hz), 8.12 (2H,
d, $J=6.5\text{Hz}$), 8.38 (2H, d, $J=9.0\text{Hz}$), 8.49 (2H, d,
 $J=9.0\text{Hz}$), 9.12 (2H, d, $J=6.5\text{Hz}$), 9.30-9.35 (1H,
m)

10 Mass (m/z) : 448 ($\text{M}^+ - \text{I}^-$)

Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{19}\text{FIN}_5\text{O}_4$:

C 47.28, H 3.28, N 11.98

Found : C 47.30, H 3.33, N 11.85

15 Preparation 14

A mixture of 4-nitrobenzamide oxime (4 g) and ethyl chlorooxoacetate (3.01 g) in dioxane (200 ml) was refluxed for 1 hour, and then borontrifluoride (1 ml) was added thereto. The whole mixture was refluxed for 12 hours.

20 After being cooled to room temperature, the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate (100 ml), washed with a saturated potassium carbonate aqueous solution, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by
25 column chromatography on silica gel with a mixture of dichloromethane and hexane (1:1) as eluent. The fractions containing the object product were collected and evaporated in vacuo to afford 5-ethoxycarbonyl-3-(4-nitrophenyl)-1,2,4-oxadiazole.

30 mp : 117-118°C

IR (Nujol) : 1740, 1345, 720 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.39 (3H, t, $J=7.1\text{Hz}$), 4.49 (2H,
q, $J=7.1\text{Hz}$), 8.32 (2H, d, $J=10.9\text{Hz}$), 8.43 (2H,
d, $J=10.9\text{Hz}$)

35

Preparation 15

A solution of di-tert-butyl-dicarbonate (1.70 g) in methylene chloride (5 ml) was added dropwise to a mixture of 4-(2-hydroxyethyl)piperidine (1.0 g) and triethylamine (1.08 ml) in methylene chloride (10 ml) at 5°C. After stirring at ambient temperature for 1 hour, the reaction mixture was poured into water. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica eluting with 3% methanol in chloroform and the fractions containing the object product were collected and evaporated to give 1-tert-butoxycarbonyl-4-(2-hydroxyethyl)piperidine (1.80 g) as an oil.

IR (Film) : 3400, 1670 cm^{-1}

NMR (CDCl_3 , δ) : 1.09-1.13 (2H, m), 1.45 (9H, s), 1.50-1.71 (5H, m), 2.62-2.75 (2H, m), 3.67-3.74 (2H, m), 4.04-4.11 (2H, m)

Mass (m/z) : 229 (M^+)

Preparation 16

(1) A solution of methanesulfonyl chloride (0.51 ml) in methylene chloride (5 ml) was added dropwise to a mixture of 4-(2-hydroxyethyl)-1-tert-butoxycarbonylpiperidine (1.43 g) and triethylamine (0.91 ml) at 5°C. After stirring at ambient temperature for 1 hour, the mixture was poured into ice water and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo to give 1-tert-butoxycarbonyl-4-(2-mesyloxyethyl)piperidine (1.37 g).

mp : 83-84°C

IR (Nujol) : 1665 cm^{-1}

NMR (CDCl_3 , δ) : 1.04-1.24 (2H, m), 1.45 (9H, m), 1.56-1.76 (5H, m), 2.63-2.76 (2H, m), 3.02 (3H, m), 4.07-4.13 (2H, m), 4.26-4.32 (2H, m)

Mass (m/z) : 307 (M^+)

The following compound was obtained according to a similar manner to that of Preparation 16-(1).

5

(2) 1-(3-Methoxybenzoyl)-4-(2-mesyloxyethyl)piperidine

IR (Film) : 3450, 2940, 1620, 1580 cm^{-1}

NMR (CDCl_3 , δ) : 1.20-1.24 (2H, br), 1.71-1.76 (5H, m), 2.66-2.70 (2H, br), 2.90-3.01 (2H, br), 3.06

10

(3H, s), 3.86 (3H, s), 4.26-4.32 (2H, s), 6.92

(1H, s), 6.93-6.99 (2H, m), 7.25-7.33 (1H, m)

Mass (m/z) : 340 (M^+-1)

Preparation 17

15 (1) A mixture of 1-tert-butoxycarbonyl-4-(2-mesyloxyethyl)piperidine (1.20 g) and potassium phthalimide (0.80 g) in N,N-dimethylformamide (15 ml) was stirred at 40°C for 2 hours. The mixture was poured into water and extracted with ethyl acetate. The extract was
20 washed with water, and dried over magnesium sulfate and evaporated in vacuo to give N-[2-[1-tert-butoxycarbonyl-piperidin-4-yl]ethyl]phthalimide (1.12 g).

mp : 112-114°C

IR (Nujol) : 1770, 1710, 1670 cm^{-1}

25

NMR ($\text{DMSO}-d_6$, δ) : 0.91-1.07 (2H, m), 1.39 (9H, s), 1.48-1.58 (3H, m), 1.67-1.73 (2H, m), 2.60-2.70 (2H, m), 3.57-3.64 (2H, m), 3.88-3.94 (2H, m), 7.80-7.90 (4H, m)

Mass (m/z) : 358 (M^+)

30.

The following compound was obtained according to a similar manner to that of Preparation 17-(1).

(2) N-[2-[1-(3-Methoxybenzoyl)piperidin-4-yl]ethyl]-
35 phthalimide

IR (Film) : 3460, 2930, 1770, 1710, 1620 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.10-1.13 (2H, m), 1.54-1.75 (5H, m), 2.71-2.94 (2H, br), 3.59-3.65 (4H, m), 3.78 (3H, s), 6.89 (1H, s), 6.98-7.02 (2H, m),

5 7.31-7.39 (1H, m), 7.80-7.90 (4H, m)

Mass (m/z) : 391 (M^+-1)

Preparation 18

(1) A mixture of N-[2-[1-tert-butoxycarbonylpiperidin-4-yl]ethyl]phthalimide (1.0 g) and hydrazine hydrate (0.16 ml) in ethanol (10 ml) was refluxed for 1 hour. After cooling to room temperature, the mixture was evaporated. The residue was chromatographed on alumina eluting with chloroform and the fractions containing the object product were collected and evaporated to give 2-[1-tert-butoxycarbonylpiperidin-4-yl]ethylamine (0.4 g) as an oil.

15

IR (Film) : 3460, 1680 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-1.18 (4H, m), 1.34-1.41 (3H, m), 1.45 (9H, s), 2.62-2.77 (4H, m), 4.04-4.10 (2H, br)

20

Mass (m/z) : 228 (M^+)

The following compounds were obtained according to a similar manner to that of Preparation 18-(1).

25

(2) 2-[1-(3-Methoxybenzoyl)piperidin-4-yl]ethylamine

IR (Film) : 3360, 3300, 2920, 1620 cm^{-1}

NMR (CDCl_3 , δ) : 1.17-1.21 (2H, m), 1.38-1.47 (4H, m), 1.56-1.67 (3H, m), 2.71-2.78 (2H, m), 2.80-2.96 (2H, m), 3.82 (3H, s), 6.92 (1H, s), 6.93-7.02 (2H, m), 7.26-7.34 (1H, m)

30

Mass (m/z) : 262 (M^+)

(3) 2-(1-Benzylpiperazin-4-yl)ethylamine

35

IR (Film) : 3350, 2940, 2800, 1590 cm^{-1}

NMR (CDCl_3 , δ) : 2.38-2.48 (10H, m), 2.75-2.81 (2H, m), 3.51 (2H, s), 7.19-7.41 (5H, m).

Mass (m/z) : 220 ($\text{M}^+ + 1$)

5 Preparation 19

(1) A mixture of 4-(2-hydroxyethyl)piperidine (21.5 g), 4-fluorobenzaldehyde (17.5 ml) and p-toluene sulfonic acid (3 mg) in benzene (200 ml) was refluxed with separating water as the benzene azeotrope. After 2 hours, the mixture was evaporated in vacuo. The residue was dissolved in methanol (200 ml) and sodium borohydride (6.3 g) was added thereto at 5°C. After stirring at ambient temperature for 1 hour, the mixture was evaporated in vacuo. 4N Hydrochloric acid (200 ml) was added to the residue and washed with ethyl acetate. The aqueous layer was made basic to pH 10 with potassium carbonate and extracted with ethyl acetate. The extract was washed with water and brine, and dried over magnesium sulfate, and evaporated in vacuo to give 1-(4-fluorobenzyl)-4-(2-hydroxyethyl)piperidine (32.0 g) as an oil.

IR (Film) : 3330, 1740 cm^{-1}

NMR (CDCl_3 , δ) : 1.21-1.58 (5H, m), 1.55-1.69 (2H, m), 1.87-2.24 (2H, m), 2.81-2.87 (2H, m), 3.43 (2H, s), 3.66 (2H, t, $J=6.5\text{Hz}$), 6.92-7.08 (2H, m), 7.23-7.36 (2H, m)

The following compound was obtained according to a similar manner to that of Preparation 19-(1).

30 (2) 4-Ethoxycarbonyl-1-benzylpiperidine

IR (Film) : 3400, 1730 cm^{-1}

Preparation 20

To a mixture of 1-(4-fluorobenzyl)-4-(2-hydroxyethyl)piperidine (10.0 g), triphenylphosphine

(13.04 g) and phthalimide (6.65 g) in tetrahydrofuran (100 ml) was added dropwise a solution of diethyl diazenedicarboxylate (7.7 ml) in tetrahydrofuran (50 ml). After stirring overnight at ambient temperature, the mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with water and brine, and dried over magnesium sulfate, and evaporated in vacuo. The residue was suspended with hexane - ether (100 ml - 100 ml) and the precipitates were removed by filtration. The filtrate was evaporated in vacuo and the residue was recrystallized from hexane to give N-[2-[1-(4-fluorobenzyl)piperidin-4-yl]ethyl]phthalimide (9.23 g).

mp : 53-54°C

IR (Nujol) : 1760, 1700, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.11-1.90 (3H, m), 1.47-1.56 (2H, m), 1.66-1.71 (2H, m), 1.80-1.91 (2H, m), 2.71-2.77 (2H, m), 3.39 (2H, s), 3.56-3.63 (2H, m), 7.07-7.17 (2H, m), 7.27-7.34 (2H, m), 7.80-7.89 (4H, m)

20

Preparation 21

A mixture of N-[2-[1-(4-fluorobenzyl)piperidin-4-yl]ethyl]phthalimide (12.7 g) and hydrazine hydrate (2.02 ml) in ethanol (150 ml) was refluxed for 2 hours. After cooling to room temperature, the mixture was evaporated in vacuo. The residue was chromatographed on alumina eluting with chloroform and the fractions containing the object product were collected and evaporated to give 2-[1-(4-fluorobenzyl)piperidin-4-yl]ethylamine (4.5 g) as an oil.

30

IR (Film) : 3350, 1600 cm^{-1}

NMR (CDCl_3 , δ) : 1.19-1.41 (7H, m), 1.61-1.66 (2H, m), 1.86-1.98 (2H, m), 2.67-2.74 (2H, m), 2.80-2.86 (2H, m), 3.43 (2H, s), 6.92-7.04 (2H, m), 7.21-7.30 (2H, m)

35

Mass (m/z) : 237 ($M^+ + 1$)

Preparation 22

To a mixture of 4-(2-hydroxyethyl)piperidine (5.0 g) and triethylamine (5.39 ml) in methylene chloride (50 ml) was added dropwise a solution of 3-methoxybenzoyl chloride (5.44 ml) in methylene chloride (15 ml) at 0°C. After stirring at ambient temperature for 1 hour, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, and dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica eluting with chloroform and the fractions containing the object product were collected and evaporated to give 2-[1-(3-methoxybenzoyl)piperidin-4-yl]ethanol (9.6 g) as an oil.

IR (Film) : 3400, 1620, 1580 cm^{-1}

NMR (CDCl_3 , δ) : 1.15-1.20 (2H, br), 1.49-1.58 (2H, m), 1.70-1.90 (5H, m), 2.80-3.00 (2H, br), 3.66-3.84 (2H, m), 3.82 (3H, s), 4.67-4.75 (1H, br), 6.92 (1H, s), 6.93-6.96 (2H, m), 7.26-7.31 (1H, m)

Mass (m/z) : 262 ($M^+ - 1$)

Preparation 23

A solution of 2-[1-(3-methoxybenzoyl)piperidin-4-yl]ethylamine (4.5 g) in tetrahydrofuran (40 ml) was added dropwise to a suspension of lithium aluminum hydride (1.63 g) in tetrahydrofuran (50 ml) under refluxing. After 30 minutes, the mixture was cooled to 0°C, and ethyl acetate (5 ml), water (2 ml), 4N sodium hydroxide (4 ml), water (2 ml) and magnesium sulfate were added thereto successively. The resulting precipitates were removed out by filtration and the filtrate was evaporated in vacuo. The residue was chromatographed on alumina eluting with 2% methanol in chloroform to give 2-[1-(3-methoxybenzyl)piperidin-4-yl]-

ethylamine (1.8 g) as an oil.

5 NMR (CDCl₃, δ) : 1.21-1.49 (7H, m), 1.61-1.66 (2H, m), 1.88-1.99 (2H, m), 2.59-2.75 (2H, m), 2.83-2.89 (2H, m), 3.46 (2H, s), 3.70 (3H, s), 6.76-6.81 (1H, m), 6.88-6.91 (2H, m), 7.18-7.27 (1H, m)
Mass (m/z) : 248 (M⁺)

Preparation 24

10 A solution of 1-benzyl-4-formylpiperidine (4.5 g) in tetrahydrofuran (20 ml) was added dropwise to a suspension of diethyl cyanomethylphosphonate (4.31 g) and sodium hydride (0.97 g, 60% suspension in oil) in tetrahydrofuran (30 ml) at 0°C under stirring. After stirring for 1 hour
15 at ambient temperature, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine and dried over magnesium sulfate, and evaporated in vacuo to give (E)-3-(1-benzylpiperidin-4-yl)-2-propenenitrile (5.5 g) as an oil.

20 NMR (DMSO-d₆, δ) : 1.34-1.73 (5H, m), 1.93-2.16 (2H, m), 2.81-2.93 (2H, m), 3.50 (2H, s), 5.22-5.33 (1H, m), 6.27-6.73 (1H, m), 7.19-7.39 (5H, m)
Mass (m/z) : 226 (M⁺)

Preparation 25

25 A mixture of (E)-3-(1-benzylpiperidin-4-yl)-2-propenenitrile (5.5 g) and platinum(IV) oxide (0.5 g) in methanol (70 ml) was hydrogenated at atmospheric pressure for 8 hours. After platinum(IV) oxide was removed by
30 filtration, the filtrate was evaporated in vacuo to give 3-(1-benzylpiperidin-4-yl)propanenitrile (2.7 g) as an oil.

IR (Film) : 2240 cm⁻¹
35 NMR (CDCl₃, δ) : 1.16-1.48 (3H, m), 1.55-1.65 (4H, m), 1.70-2.02 (2H, m), 2.02-2.39 (2H, m),

2.86-2.91 (2H, m), 3.49 (2H, s), 7.23-7.41 (5H, m)

Mass (m/z) : 228 (M^+)

5 Preparation 26

 A mixture of 3-(1-benzylpiperidin-4-yl)propanenitrile (0.5 g), Raney nickel (0.3 ml) and a conc. ammonia aqueous solution (1 ml) in ethanol (10 ml) was hydrogenated at atmospheric pressure for 6 hours. After Raney nickel was removed by filtration, the filtrate was evaporated in vacuo. The residue was chromatographed on alumina eluting with 2% methanol in chloroform and the fractions containing the object product were collected and evaporated to give 3-(1-benzylpiperidin-4-yl)propylamine (0.4 g) as an oil.

IR (Film) : 3350, 3270 cm^{-1}

NMR (CDCl_3 , δ) : 1.23-1.44 (9H, m), 1.62-1.67 (2H, m), 1.86-1.97 (2H, m), 2.63-2.70 (2H, m), 2.84-2.90 (2H, m), 3.48 (2H, s), 7.23-7.32 (5H, m)

Preparation 27

 To a mixture of 1-benzyl-4-ethoxycarbonylpiperidine (6.88 g) and formamide (3.71 ml) in N,N-dimethylformamide (30 ml) was added 28% sodium methoxide solution in methanol (4.0 ml) at 100°C under stirring. After stirring at 100°C for 1 hour, the mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with water and brine and dried over magnesium sulfate, and evaporated in vacuo. The residue was recrystallized from ether to give 1-benzyl-4-carbamoylpiperidine (2.8 g).

mp : 158-160°C

NMR ($\text{DMSO}-d_6$, δ) : 1.44-1.70 (4H, m), 1.84-2.13 (3H, m), 2.77-2.83 (2H, m), 3.43 (2H, s), 7.23-7.40 (5H, m)

Mass (m/z) : 218 (M^+)

Preparation 28

A solution of 1-benzyl-4-carbamoylpiperidine (2.5 g)
5 in tetrahydrofuran (10 ml) was added dropwise to 1N
solution of diborane-tetrahydrofuran complex in
tetrahydrofuran (34.3 ml) at 0°C and then the mixture was
refluxed for 3 hours. After cooling to room temperature,
6N hydrochloric acid (10 ml) was added thereto. The
10 mixture was stirred overnight and concentrated in vacuo.
The residue was dissolved in ethyl acetate and made basic
with 5N sodium hydroxide. The separated organic layer was
washed with water and brine and dried over magnesium
sulfate, and evaporated in vacuo to give
15 (1-benzylpiperidin-4-yl)methylamine (1.4 g) as an oil.

NMR ($CDCl_3$, δ) : 1.22-1.31 (2H, m), 1.68-2.05 (5H,
m), 2.35-2.45 (2H, m), 2.54-2.61 (2H, m),
2.87-2.92 (2H, m), 3.49 (2H, s), 7.26-7.37 (5H,
m)

20 Mass (m/z) : 204 (M^+)

Preparation 29

To a solution of hydroxylamine hydrochloride (0.23 g)
in hot ethanol (10 ml) was added 1N sodium ethoxide (3.44
25 ml) and stirred at ambient temperature for 20 minutes.
The resulting precipitates were removed filtration. To
the filtrate was added 2-acetoxy-5-(1-benzylpiperidin-4-
yl)pentanethioamide (1.0 g) and the mixture was stirred
overnight. The solution was evaporated in vacuo and the
30 residue was extracted with ethyl acetate. The extract was
washed with water, dried over magnesium sulfate and
evaporated in vacuo to give 2-acetoxy-5-(1-
benzylpiperidin-4-yl)-1-hydroxyiminopentylamine (0.68 g)
as an oil.

35 IR (Film) : 3500, 3400, 1730, 1670, 1580 cm^{-1}

NMR (CDCl_3 , δ) : 1.10-1.30 (7H, m), 1.60-1.64 (2H, m), 1.71-1.88 (2H, m), 1.93-1.99 (2H, m), 2.09 (3H, s), 2.86-2.92 (2H, m), 3.51 (2H, m), 4.63 (2H, s), 5.21 (1H, t, $J=7.1\text{Hz}$), 7.24-7.33 (5H, m)

Mass (m/z) : 348 (M^+)

Preparation 30

A solution of 2-acetoxy-5-(1-benzylpiperidin-4-yl)-1-hydroxyiminopentylamine (0.59 g) in tetrahydrofuran (5 ml) was added dropwise to a solution of 4-nitrobenzoyl chloride (0.29 g) in tetrahydrofuran (5 ml) and the mixture was stirred overnight at ambient temperature and extracted with ethyl acetate. The extract was washed with a sodium hydrogencarbonate aqueous solution and water, dried over magnesium sulfate and evaporated in vacuo to give 2-acetoxy-5-(1-benzylpiperidin-4-yl)-1-(4-nitrobenzoyloxyimino)pentylamine (0.35 g).

mp : 149-150°C

IR (Film) : 3450, 3350, 1720, 1630, 1600 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.10-1.30 (7H, m), 1.58-1.63 (2H, m), 1.77-1.94 (4H, m), 2.08 (3H, s), 2.74-2.79 (2H, m), 3.42 (2H, s), 5.09 (1H, t, $J=7.0\text{Hz}$), 6.86 (2H, s), 7.22-7.30 (5H, m), 8.30 (2H, d, $J=9.1\text{Hz}$), 8.37 (2H, d, $J=9.1\text{Hz}$)

Elemental Analysis Calcd. for $\text{C}_{26}\text{H}_{32}\text{N}_4\text{O}_6$:

C 62.88, H 6.49, N 11.28

Found : C 62.68, H 6.41, N 11.14

Mass (m/z) : 497 (M^++1)

Preparation 31

(1) A mixture of N-ethoxalyl-N'-(4-methylphenyl)hydrazine (3 g) and phosphorus pentoxide (9 g) in toluene (45 ml) was refluxed for 1 hour with stirring. After being cooled to room temperature, the reaction mixture was poured into

a mixture of ice-water (50 ml) and ethyl acetate (50 ml). The organic layer was successively washed with a saturated sodium hydrogencarbonate aqueous solution and brine, dried over magnesium sulfate and evaporated in vacuo to afford
5 2-ethoxycarbonyl-5-(4-methylthiophenyl)-1,3,4-oxadiazole (1.89 g).

mp : 90-92°C

IR (Nujol) : 1745, 1600, 1180, 840 cm^{-1}

10 NMR (DMSO- d_6 , δ) : 1.37 (3H, t, $J=7.1\text{Hz}$), 2.57 (3H, s), 4.46 (2H, q, $J=7.1\text{Hz}$), 7.48 (2H, d, $J=8.6\text{Hz}$), 7.96 (2H, d, $J=8.6\text{Hz}$)

MASS (m/z) : 264 (M^+)

Elemental Analysis Calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_3\text{S}$:

C 54.53, H 4.57, N 10.59

15 Found : C 54.68, H 4.49, N 10.51

The following compounds were obtained according to a similar manner to that of Preparation 31-(1).

20 (2) 2-Ethoxycarbonyl-5-((E)-2-(4-cyanophenyl)vinyl)-1,3,4-oxadiazole

mp : 182-183°C

IR (Nujol) : 2220, 1730, 1180 cm^{-1}

25 NMR (DMSO- d_6 , δ) : 1.37 (3H, t, $J=7.1\text{Hz}$), 4.45 (2H, q, $J=7.1\text{Hz}$), 7.60 (2H, d, $J=16.5\text{Hz}$), 7.83 (2H, d, $J=16.5\text{Hz}$), 7.92 (2H, d, $J=8.4\text{Hz}$), 8.05 (2H, d, $J=8.4\text{Hz}$)

30 (3) 2-Ethoxycarbonyl-5-(4-nitrophenyl)-1,3,4-oxadiazole

mp : 148-149°C

IR (Nujol) : 1735, 1520, 1340, 1200 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.39 (3H, t, $J=7.1\text{Hz}$), 4.49 (2H, q, $J=7.1\text{Hz}$), 8.35 (2H, d, $J=8.9\text{Hz}$), 8.44 (2H, d, $J=8.9\text{Hz}$)

35

Preparation 32

(1) To a solution of 2-ethoxycarbonyl-5-(4-methylthio-phenyl)-1,3,4-oxadiazole (0.7 g) in chloroform (14 ml), m-chloroperoxybenzoic acid (0.57 g) was added dropwise at 4-6°C with stirring. After 30 minutes, the reaction mixture was extracted with chloroform (50 ml), washed with a sodium iodide aqueous solution, a sodium thiosulfate aqueous solution, a sodium hydrogencarbonate aqueous solution and brine successively and dried over magnesium sulfate. After evaporating the solvent, the residue was crystallized from diethyl ether to afford 2-ethoxy-carbonyl-5-(4-methylsulfinylphenyl)-1,3,4-oxadiazole.

mp : 129-131°C

IR (Nujol) : 1745, 1190, 1050 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.39 (3H, t, $J=7.1\text{Hz}$), 2.85 (3H, s), 4.48 (2H, q, $J=7.1\text{Hz}$), 7.95 (2H, d, $J=8.5\text{Hz}$), 8.24 (2H, d, $J=8.5\text{Hz}$)

Mass (m/z) : 280 (M^+)

Elemental Analysis Calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_4\text{S}$:

C 51.42, H 4.31, N 9.99

Found : C 51.61, H 4.37, N 9.97

The following compound was obtained according to a similar manner to that of Preparation 32-(1).

(2) 2-Ethoxycarbonyl-5-(4-mesylphenyl)-1,3,4-oxadiazole

mp : 177-178°C

IR (Nujol) : 1740, 1300, 1200, 850 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.38 (3H, t, $J=7.1\text{Hz}$), 3.33 (3H, s), 4.48 (2H, q, $J=7.1\text{Hz}$), 8.18 (2H, d, $J=8.0\text{Hz}$), 8.33 (2H, d, $J=8.0\text{Hz}$)

Mass (m/z) : 296 (M^+)

Elemental Analysis Calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_5\text{S}$:

C 48.64, H 4.08, N 9.45

Found : C 48.70, H 4.06, N 9.41

Example 1

A mixture of 3-ethoxycarbonyl-5-(quinuclidin-3-yl)-1,2,4-oxadiazole (0.2 g) and 1-benzyl-4-(2-aminoethyl)-piperidine (0.26 g) was stirred and heated at 100°C for 2
5 hours. The cooled mixture was chromatographed on alumina eluting with chloroform to give 5-(quinuclidin-3-yl)-3-
[2-(1-benzylpiperidin-4-yl)ethyl]carbamoyl]-1,2,4-oxadiazole as an oil. The compound was treated with an
ethanol solution of hydrogen chloride, the solution was
10 evaporated in vacuo and the residue was powdered with
ether to give 5-(quinuclidin-3-yl)-3-[[2-(1-benzylpiperidin-4-yl)ethyl]carbamoyl]-1,2,4-oxadiazole
dihydrochloride (0.2 g).

mp : 210°C (dec.)
15 IR (Film) : 3400, 1670, 1560 cm⁻¹
NMR (DMSO-d₆, δ) : 1.50-1.85 (9H, m), 2.85-3.04 (3H, m), 3.24-3.91 (13H, m), 4.22, 4.25 (total 2H, s), 7.43-7.46 (3H, m), 7.60-7.63 (2H, m), 9.07 (1H, t, J=6Hz), 10.83 (1H, br), 11.09 (1H, br)
20 Mass (M/z) : 423 (M⁺ of free compound)

Example 2

To a suspension of sodium hydride (0.4 g) in N,N-dimethylformamide was added 3-amino-5-(quinuclidin-3-yl)-1,2,4-oxadiazole (0.2 g) at 0°C and the mixture was
25 stirred for 1 hour. To the mixture was added (1-benzylpiperidin-4-yl)acetyl chloride hydrochloride (2.53 g) during 30 minutes at 0°C. After stirred for additional 1 hour. The mixture was quenched with water
30 and extracted with ethyl acetate. The extract was washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on alumina with chloroform to give
3-{{1-benzylpiperidin-4-yl}acetylamino}-5-(quinuclidin-3-yl)-1,2,4-oxadiazole (0.11 g).
35

mp : 133-134°C

IR (Nujol) : 1690, 1610, 1550, 1535 cm^{-1}

NMR (CDCl_3 , δ) : 1.28-1.47 (4H, m), 1.73-1.78 (5H, m),
1.93-2.05 (3H, m), 2.25-2.30 (3H, m),
2.79-3.03 (5H, m), 3.13-3.18 (3H, m), 3.49 (2H, s),
4.07-4.12 (1H, m), 7.23-7.32 (5H, m)

Mass (M/Z) : 411 (M^+)

Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{31}\text{N}_5\text{O}_2 \cdot 0.2\text{H}_2\text{O}$:

C 66.86, H 7.66, N 16.95

Found : C 66.74, H 7.67, N 16.96

Example 3

The following compounds were obtained according to a similar manner to that of Example 1.

(1) 3-[[2-(1-Methylpiperidin-4-yl)ethyl]carbamoyl]-5-quinuclidin-3-yl)-1,2,4-oxadiazole

mp : 141-142°C

IR (Nujol) : 3150, 1680, 1540 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.09-1.84 (13H, m), 2.11 (3H, s),
2.16-2.17 (1H, m), 2.68-2.81 (6H, m), 3.17-3.33 (5H, m), 8.93 (1H, m)

Mass (m/z) : 347 (M^+)

Elemental Analysis Calcd. for $\text{C}_{18}\text{H}_{29}\text{N}_5\text{O}_2$:

C 62.22, H 8.41, N 20.15

Found : C 62.11, H 8.67, N 20.09

(2) 3-[[4-(1-Benzylpiperidin-4-yl)butyl]carbamoyl]-5-(quinuclidin-3-yl)-1,2,4-oxadiazole dihydrochloride

IR (Film) : 3300, 1680, 1540 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.23-2.02 (16H, m), 2.82-3.23 (2H, m),
3.27-3.39 (6H, m), 3.60-3.92 (3H, m), 4.22-4.45 (4H, m),
7.42-7.44 (3H, m), 7.63-7.65 (2H, m), 9.05 (1H, t, $J=6.0\text{Hz}$)

Mass (m/z) : 451 (M^+ of free compound)

Example 4

A mixture of 3-ethoxycarbonyl-5-(quinuclidin-3-yl)-1,2,4-oxadiazole (0.3 g) and 4-amino-1-benzylpiperidine (0.3 ml) was heated at 100°C for 1 hour. After cooling to room temperature, the mixture was chromatographed on alumina eluting with 5% methanol-chloroform and treated with an ethanol solution of hydrogen chloride to give 3-[(1-benzylpiperidin-4-yl)carbamoyl]-5-(quinuclidin-3-yl)-1,2,4-oxadiazole dihydrochloride (0.15 g) as an oil.

IR (Film) : 3300, 1680, 1540 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.71-2.08 (7H, m), 3.05-3.11 (2H, m), 3.29-3.33 (5H, m), 3.61-3.73 (2H, m), 3.79-3.97 (2H, m), 4.26-4.42 (5H, m), 7.44-7.47 (3H, m), 7.67-7.77 (2H, m), 9.29 (1H, d, $J=7.5\text{Hz}$)

Mass (m/z) : 395 (M^+ of free compound)

Example 5

(1) A mixture of 4-(1-benzylpiperidin-4-yl)butanamide oxime (1.0 g), sodium hydride (0.15 g) and molecular sieves 4A (2.0 g) in tetrahydrofuran (50 ml) was stirred at ambient temperature for 30 minutes. To the mixture was added dropwise a solution of methyl 3-quinuclidine carboxylate (0.49 g) in tetrahydrofuran (10 ml) and refluxed for 6 hours. After cooling to room temperature, the mixture was poured into water and extracted with ethyl acetate. The extracts were successively washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on alumina eluting with chloroform to give 3-[3-(1-benzylpiperidin-4-yl)-propyl]-5-(quinuclidin-3-yl)-1,2,4-oxadiazole (0.5 g) as an oil.

IR (Film) : 1570, 1490 cm^{-1}

NMR (CDCl_3 , δ) : 1.26-1.93 (16H, m), 2.70 (2H, t, $J=7.4\text{Hz}$), 2.83-2.94 (6H, m), 3.10-3.41 (3H, m),

- 93 -

3.47 (2H, s), 7.23-7.32 (5H, m)
Mass (m/z) : 394 (M^+)

The following compound was obtained according to a
5 similar manner to that of Example 5-(1).

(2) 3-[3-(1-Methylpiperidin-4-yl)propyl]-5-(quinuclidin-
3-yl)-1,2,4-oxadiazole

IR (Film) : 3350, 1570 cm^{-1}

10 NMR (CDCl_3 , δ) : 1.25-1.89 (16H, m), 2.26 (3H, s),
2.71 (2H, t, $J=7.2\text{Hz}$), 2.80-2.94 (6H, m),
3.12-3.41 (3H, m)

Mass (m/z) : 318 (M^+)

15 Example 6

(1) A mixture of 3-ethoxycarbonyl-5-(4-nitrophenyl)-
1,2,4-oxadiazole (1 g) and 4-(2-aminoethyl)-1-
benzylpiperidine (0.83 g) was heated at 130°C for 1 hour.
After cooling to room temperature, the residue was
20 subjected to column chromatography on silica gel using
chloroform-methanol (20:1) as an eluent. The fractions
containing the object compound were combined and
evaporated. The residue was dissolved in ethanol, added
to fumaric acid (0.22 g) and recrystallized to afford
25 3-[(2-(1-benzylpiperidin-4-yl)ethyl)carbamoyl]-5-(4-
nitrophenyl)-1,2,4-oxadiazole fumarate (0.89 g).

mp : 224-225°C (dec.)

IR (Nujol) : 3275, 1670, 1525, 1345 cm^{-1}

30 NMR ($\text{DMSO}-d_6$, δ) : 1.1-1.6 (5H, m), 1.65-1.8 (2H,
m), 2.0-2.3 (2H, m), 2.8-3.0 (2H, m), 3.3-3.5
(2H, m), 3.64 (2H, s), 6.59 (2H, s), 7.2-7.4
(5H, m), 8.40 (2H, d, $J=6.9\text{Hz}$), 8.48 (2H, d,
 $J=6.9\text{Hz}$), 9.15 (1H, t, $J=5.7\text{Hz}$)

Elemental Analysis Calcd. for $\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_8$:

35 C 58.79, H 5.29, N 12.69

Found : C 58.51, H 5.38, N 12.69

The following compounds were obtained according to a similar manner to that of Example 6-(1).

- 5 (2) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methoxyphenyl)-1,2,4-oxadiazole fumarate
mp : 213-214°C (dec.)
IR (Nujol) : 3320, 1670, 1605 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.2-1.6 (5H, m), 1.7-1.9 (2H, m),
2.3-2.5 (2H, m), 2.9-3.2 (2H, m), 3.3-3.5 (2H,
10 m), 3.82 (2H, s), 3.89 (3H, s), 6.60 (2H, s),
7.20 (2H, d, $J=8.9\text{Hz}$), 7.3-7.5 (5H, m), 8.09
(2H, d, $J=8.9\text{Hz}$), 9.03 (1H, t, $J=5.6\text{Hz}$)
Elemental Analysis Calcd. for $\text{C}_{28}\text{H}_{32}\text{N}_4\text{O}_7$:
C 62.67, H 6.01, N 10.44
15 Found : C 62.68, H 6.08, N 10.40
- (3) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(3-nitrophenyl)-1,2,4-oxadiazole fumarate
mp : 196-198°C
20 IR (Nujol) : 3340, 1680, 1340, 980 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.9-3.0 (2H, m), 3.3-3.4 (2H,
m), 3.65 (2H, s), 6.59 (2H, s), 7.3-7.4 (5H, m),
7.9-8.0 (1H, m), 8.5-8.6 (2H, m), 8.84-8.86 (1H,
25 m), 9.16 (1H, t, $J=5.3\text{Hz}$)
Elemental Analysis Calcd. for $\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_8$:
C 58.79, H 5.29, N 12.69
Found : C 58.63, H 5.12, N 12.59
- 30 (4) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-phenyl-1,2,4-oxadiazole fumarate
mp : 218-219°C (dec.)
IR (Nujol) : 3290, 1670, 1550 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.7-1.8 (2H, m),
35 2.1-2.4 (2H, m), 2.9-3.1 (2H, m), 3.2-3.45 (2H,

m), 3.70 (2H, s), 6.59 (2H, s), 7.3-7.4 (5H, m),
7.6-7.8 (3H, m), 8.1-8.2 (2H, m), 9.07 (1H, t,
J=5.7Hz)

- 5 (5) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methylphenyl)-1,2,4-oxadiazole fumarate
mp : 219-220°C (dec.)
IR (Nujol) : 3250, 1670, 830 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.65-1.8 (2H,
10 m), 2.1-2.3 (2H, m), 2.43 (3H, s), 2.9-3.05 (2H,
m), 3.3-3.4 (2H, m), 3.69 (2H, s), 6.59 (2H, s),
7.2-7.4 (5H, m), 7.48 (2H, d, J=8.1Hz), 8.03
(2H, d, J=8.1Hz), 9.03 (1H, t, J=5.8Hz)
- 15 (6) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-trifluoromethylphenyl)-1,2,4-oxadiazole fumarate
mp : 200-201°C
IR (Nujol) : 3300, 1710, 1670, 1600 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.21-1.51 (5H, m), 1.71-1.76 (2H,
20 m), 2.12-2.23 (2H, m), 2.90-2.96 (2H, m),
3.32-3.50 (2H, m), 6.59 (2H, s), 7.28-7.34 (5H,
m), 8.05 (2H, d, J=8.3Hz), 8.37 (2H, d,
J=8.3Hz), 9.13 (1H, t, J=5.7Hz)
Mass (m/z) : 458 (M^+ of free compound)
25 Elemental Analysis Calcd. for $\text{C}_{28}\text{H}_{29}\text{F}_3\text{N}_4\text{O}_6$:
C 58.53, H 5.08, N 9.75
Found : C 58.51, H 5.14, N 9.65
- 30 (7) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methylthiophenyl)-1,2,4-oxadiazole fumarate
mp : 199-201°C (dec.)
IR (Nujol) : 3320, 1710, 1670, 970 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.65-1.8 (2H,
35 m), 2.1-2.35 (2H, m), 2.58 (3H, s), 2.9-3.1 (2H,
m), 3.2-3.4 (2H, m), 3.74 (2H, s), 6.59 (2H, s),

7.3-7.5 (5H, m), 7.51 (2H, d, J=8.6Hz), 8.04
(2H, d, J=8.6Hz), 9.04 (1H, t, J=5.8Hz)

Elemental Analysis Calcd. for $C_{28}H_{32}N_4O_6S$:

C 60.85, H 5.83, N 10.13

5

Found : C 60.84, H 5.75, N 10.09

(8) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(pyridin-3-yl)-1,2,4-oxadiazole fumarate

mp : 190-191°C

10 IR (Nujol) : 3300, 1710, 1670, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.06-1.34 (5H, m), 1.73-1.78 (2H, m), 2.19-2.29 (2H, m), 2.51 (2H, br), 2.94-3.00 (2H, m), 3.32-3.35 (2H, m), 3.73 (2H, s), 6.59 (2H, s), 7.36 (5H, m), 7.71 (1H, dd, J=4.9, 8.0Hz), 8.52 (1H, d, J=8.0Hz), 8.90 (1H, d, J=4.9Hz), 9.12 (1H, br), 9.31 (1H, s)

15

Mass (m/z) : 391 (M^+ of free compound)

(9) 5-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-3-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

20

mp : 235-237°C (dec.)

IR (Nujol) : 3250, 1680, 1345, 720 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m), 2.1-2.3 (2H, m), 2.8-3.0 (2H, m), 3.2-3.4 (2H, m), 3.68 (2H, m), 6.59 (2H, m), 7.2-7.4 (5H, m), 8.31 (2H, d, J=7Hz), 8.45 (2H, d, J=7Hz), 9.55 (1H, t, J=5.7Hz)

25

Example 7

30 (1) To a solution of 3-ethoxycarbonyl-5-(4-methylthiophenyl)-1,2,4-oxadiazole (0.8 g) in chloroform (16 ml), m-chloroperbenzoic acid (0.65 g) was added portionwise at 4-6°C with stirring. After 30 minutes, the reaction mixture was extracted with chloroform (50 ml),
35 washed with an aqueous sodium iodide solution, an aqueous

sodium thiosulfate solution, an aqueous sodium hydrogencarbonate solution and brine successively and dried over magnesium sulfate. After evaporating the solvent, to the residue was added 4-(2-aminoethyl)-1-benzylpiperidine (0.63 g) and the mixture was heated at 130°C for 1 hour. The following procedures were employed according to a similar manner to that of Example 6-(1) to afford 3-[(2-(1-benzylpiperidin-4-yl)ethyl)carbamoyl]-5-(4-methylsulfinylphenyl)-1,2,4-oxadiazole fumarate (0.97 g).

mp : 202-203°C (dec.)

IR (Nujol) : 3325, 1675, 1540 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.2-1.6 (5H, m), 1.6-1.8 (2H, m), 2.1-2.3 (2H, m), 2.85 (3H, s), 2.9-3.1 (2H, m), 3.2-3.4 (2H, m), 3.68 (2H, s), 6.59 (2H, s), 7.2-7.4 (5H, m), 7.98 (2H, d, $J=6.8\text{Hz}$), 8.32 (2H, d, $J=6.8\text{Hz}$), 9.10 (1H, t, $J=5.8\text{Hz}$)

The following compound was obtained according to a similar manner to that of Example 7-(1).

(2) 3-[(2-(1-Benzylpiperidin-4-yl)ethyl)carbamoyl]-5-(4-methylsulfonylphenyl)-1,2,4-oxadiazole 1/2 fumarate

mp : 171-174°C (dec.)

IR (Nujol) : 3330, 1670, 1150 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m), 1.9-2.2 (2H, m), 2.75-2.95 (2H, m), 3.2-3.4 (2H, m), 3.35 (3H, s), 3.58 (2H, s), 6.57 (1H, s), 7.2-7.4 (5H, m), 8.22 (2H, d, $J=8.6\text{Hz}$), 8.40 (2H, d, $J=8.6\text{Hz}$), 9.14 (1H, t, $J=5, 8\text{Hz}$)

Example 8

A suspension of 5-(1-benzylpiperidin-4-yl)-1-hydroxyiminopentylamine (1.0 g) and molecular sieves 3A (2.0 g) in tetrahydrofuran (50 ml) was stirred at ambient

temperature for 30 minutes and then sodium hydride (0.14 g) was added thereto. After 30 minutes, a solution of ethyl 4-methoxybenzoate (0.56 g) in tetrahydrofuran was added to the mixture over 5 minutes. The mixture was heated under reflux overnight. After cooling, the reaction was filtered and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and water. The extract was washed with brine, dried over magnesium sulfate and removed in vacuo. The residue was chromatographed on silica gel eluting with chloroform/methanol (95:5) and the fractions containing the object compound were combined and evaporated. The residue was dissolved in ethanol (5 ml), added to fumaric acid (0.31 g) and recrystallized to afford 3-[4-(1-benzylpiperidin-4-yl)butyl]-5-(4-methoxyphenyl)-1,2,4-oxadiazole fumarate (1.01 g).

mp : 151-152°C

IR (Nujol) : 1690, 1640, 1610, 1560, 1520 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 1.03-1.26 (7H, m), 1.63-1.69 (4H, m), 2.21 (2H, t, $J=11.2\text{Hz}$), 2.73 (2H, t, $J=8.0\text{Hz}$), 2.93 (2H, d, $J=11.4\text{Hz}$), 3.70 (2H, s), 3.87 (3H, s), 6.59 (2H, s), 7.15 (2H, d, $J=10.0\text{Hz}$), 7.29-7.37 (5H, m), 8.03 (2H, d, $J=10.0\text{Hz}$)

Mass (m/z) : 405 (M^+)

Example 9

To a solution of 3-[(2-(1-benzylpiperidin-4-yl)-ethyl)carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole (1 g) in N,N -dimethylformamide (10 ml) was added sodium hydride (0.1 g) under ice cooling. After stirring for 30 minutes, methyl iodide (0.41 g) was added to this solution and the mixture was stirred for 1 hour. The mixture was quenched with an aqueous ammonium chloride solution and extracted with ethyl acetate (50 ml). The extract was successively

washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was column chromatographed on silica gel (150 ml) with chloroform/methanol = 25/1 as an eluent. The fractions
5 containing the object compound were combined and evaporated in vacuo. The residue was dissolved in ethanol (10 ml) and added to fumaric acid (0.13 g) in ethanol (10 ml). The crystalline residue was collected and dried in vacuo to afford 3-[N-{2-(1-benzylpiperidin-4-yl)ethyl}-N-methylcarbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole
10 fumarate (0.53 g).

mp : 124-125°C (dec.)

IR (Nujol) : 3550, 3440, 1720, 1640, 1180 cm^{-1}

15 NMR (DMSO- d_6 , δ) : 1.0-1.8 (7H, m), 2.0-2.3 (2H, m), 2.7-3.1 (2H, m), 3.05 (3H, s), 3.3-3.7 (2H, m), 3.61, 3.69 (total 2H, each s), 6.59 (2H, s), 7.2-7.5 (5H, m), 8.41 (2H, d, $J=8.8\text{Hz}$), 8.46 (2H, d, $J=8.8\text{Hz}$)

20 Example 10

(1) To a mixture of 3-[[2-(piperidin-4-yl)ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole hydrochloride (0.7 g), 4-fluorobenzaldehyde (0.24 g) and molecular sieves 4A (1.0 g) in methanol (7 ml) was added
25 1M solution of potassium hydroxide in methanol (1.93 ml). After stirring for 5 hours at ambient temperature, sodium borohydride (73 mg) was added to the mixture under ice cooling. The mixture was stirred for 20 minutes and evaporated in vacuo. The residue was dissolved in ethyl
30 acetate and washed with water, brine, dried over magnesium sulfate and evaporated in vacuo to give a residue containing 3-[[2-{1-(4-fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole. The residue and fumaric acid (0.11 g) were dissolved in hot
35 ethanol (10 ml) and recrystallized to afford 3-[[2-{1-(4-

fluorobenzyl)piperidin-4-yl}ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate (0.50 g).

mp : 233-235°C (dec.)

IR (Nujol) : 3280, 2230, 1720, 1670 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.19-1.29 (5H, m), 1.47-1.51 (2H, m), 2.07-2.18 (2H, m), 2.87-2.92 (2H, m), 3.31-3.34 (2H, m), 3.62 (2H, s), 6.59 (2H, s), 7.16 (2H, dd, $J=8.5$, 8.5Hz), 7.38 (2H, dd, $J=5.7$, 8.5Hz), 8.14 (2H, d, $J=8.4$ Hz), 8.31 (2H, d, $J=8.4$ Hz), 9.12 (1H, m)

10 Mass (m/z) : 432 (M^+ of free compound)

Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{24}\text{FN}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 61.19, H 5.13, N 12.74

Found : C 61.16, H 5.02, N 12.65

15

The following compounds were obtained according to a similar manner to that of Example 10-(1).

20 (2) 3-[[2-{1-(3-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 251-253°C (dec.)

IR (Nujol) : 3300, 2230, 1710, 1675 cm^{-1}

25 NMR (DMSO- d_6 , δ) : 1.17-1.28 (3H, m), 1.48-1.51 (2H, m), 1.69-1.74 (2H, m), 2.00-2.11 (2H, m), 2.83-2.88 (2H, m), 3.31-3.43 (2H, m), 3.58 (2H, s), 6.60 (2H, s), 7.06-7.18 (3H, m), 7.32-7.43 (1H, m), 8.14 (2H, d, $J=8.5$ Hz), 8.31 (2H, d, $J=8.5$ Hz), 9.09-9.12 (1H, m)

Mass (m/z) : 433 (M^+ of free compound)

30 Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{24}\text{FN}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 61.19, H 5.13, N 12.74

Found : C 61.11, H 5.11, N 12.62

35 (3) 3-[[2-{1-(2-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate

mp : 231-232°C

IR (Nujol) : 3300, 2230, 1710, 1680 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.18-1.29 (3H, m), 1.47-1.50 (2H, m), 1.71-1.76 (2H, m), 2.14-2.24 (2H, m), 2.91-2.96 (2H, m), 3.29-3.36 (2H, m), 3.70 (2H, s), 6.60 (2H, s), 7.15-7.24 (2H, m), 7.33-7.48 (2H, m), 8.13 (2H, d, $J=8.5\text{Hz}$), 8.32 (2H, d, $J=8.5\text{Hz}$)

Mass (m/z) : 433 (M^+ of free compound)

Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{29}\text{FN}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 61.19, H 5.13, N 12.74

Found : C 61.29, H 5.07, N 12.65

(4) 3-[[2-{1-(4-Cyanobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 190-191°C

IR (Nujol) : 3300, 2210, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.18-1.49 (5H, m), 1.69-1.74 (2H, m), 2.03-2.13 (2H, m), 2.81-2.87 (2H, m), 3.32-3.35 (2H, m), 3.65 (2H, m), 6.61 (2H, m), 7.53 (2H, d, $J=7.8\text{Hz}$), 7.80 (2H, d, $J=7.8\text{Hz}$), 8.14 (2H, d, $J=8.2\text{Hz}$), 8.31 (2H, d, $J=8.2\text{Hz}$), 9.08-9.12 (1H, m)

(5) 3-[[2-{1-(4-Chlorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 216-218°C

IR (Nujol) : 3280, 2210, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.09-1.50 (5H, m), 1.68-1.73 (2H, m), 1.98-2.09 (2H, m), 2.81-2.86 (2H, m), 3.31-3.34 (2H, m), 3.54 (2H, s), 6.60 (2H, s), 7.31-7.42 (4H, m), 8.14 (2H, d, $J=8.5\text{Hz}$), 8.31 (2H, d, $J=8.5\text{Hz}$), 9.08-9.12 (1H, m)

Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{24}\text{ClN}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 59.41, H 4.98, N 12.37

Found : C 59.03, H 5.03, N 12.37

(6) 3-[[2-{1-(4-Methoxybenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 117-119°C

IR (Nujol) : 2210, 1680 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.29-1.48 (5H, m), 1.72-1.77 (2H, m), 2.20-2.25 (2H, m), 2.95-3.00 (2H, m), 3.34-3.50 (2H, m), 3.69 (2H, s), 3.75 (3H, s), 6.57 (2H, s), 6.91 (2H, d, $J=8.1\text{Hz}$), 7.28 (2H, d, $J=8.1\text{Hz}$), 8.14 (2H, d, $J=8.2\text{Hz}$), 8.31 (2H, d, $J=8.2\text{Hz}$), 9.08-9.12 (1H, m)

(7) 3-[[2-{1-(4-Nitrobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 217-218°C

15 IR (Nujol) : 3600, 3440, 3300, 2240, 1720, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.18-1.51 (5H, m), 1.69-1.74 (2H, m), 2.00-2.10 (2H, m), 2.80-2.86 (2H, m), 3.32-3.35 (2H, m), 3.66 (2H, s), 6.62 (2H, s), 7.60 (2H, d, $J=8.7\text{Hz}$), 8.14 (2H, d, $J=8.5\text{Hz}$), 8.20 (2H, d, $J=8.7\text{Hz}$), 8.32 (2H, d, $J=8.5\text{Hz}$), 9.08-9.14 (1H, m)

Mass (m/z) : 460 (M^+ of free compound)

Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{24}\text{N}_6\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 58.32, H 4.89, N 14.57

25 Found : C 58.81, H 4.95, N 14.57

(8) 3-[[2-{1-(4-Methylbenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate
mp : 228-229°C

30 IR (Nujol) : 3300, 2240, 1720, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.21-1.31 (5H, m), 1.47-1.50 (2H, m), 2.13-2.24 (2H, m), 2.29 (3H, s), 2.91-2.97 (2H, m), 3.31-3.34 (2H, m), 3.65 (2H, s), 6.58 (2H, s), 7.14 (2H, d, $J=8.0\text{Hz}$), 7.23 (2H, d, $J=8.0\text{Hz}$), 8.14 (2H, d, $J=8.5\text{Hz}$), 8.31 (2H, d, $J=8.5\text{Hz}$)

J=8.5Hz), 9.08-9.14 (1H, m)

Example 11

The following compounds were obtained according to a similar manner to that of Example 6-(1).

(1) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-[(E)-2-(4-cyanophenyl)ethenyl]-1,2,4-oxadiazole fumarate
mp : 209-210°C (dec.)

IR (Nujol) : 3300, 2225, 1680, 1640 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.8-3.0 (2H, m), 3.2-3.4 (2H, m), 3.62 (2H, s), 6.59 (2H, s), 7.33 (5H, m),
7.62 (2H, d, J=16.4Hz), 7.96 (2H, d, J=8.5Hz),
7.80 (2H, d, J=16.4Hz), 8.05 (2H, d, J=8.5Hz),
9.03 (1H, t, J=5.7Hz)

Elemental Analysis Calcd. for $\text{C}_{26}\text{H}_{27}\text{N}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 64.62, H 5.60, N 12.55

Found : C 64.68, H 5.58, N 12.56

(2) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-[(E)-2-(4-cyanophenyl)ethenyl]-1,3,4-oxadiazole fumarate
mp : 214-215°C (dec.)

IR (Nujol) : 3285, 2225, 1710, 1690 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.1-2.3 (2H, m), 2.8-3.0 (2H, m), 3.2-3.4 (2H, m), 3.66 (2H, s), 6.59 (2H, s), 7.33 (5H, s),
7.62 (2H, d, J=16.5Hz), 7.79 (2H, d, J=16.5Hz),
7.93 (2H, d, J=8.5Hz), 8.02 (2H, d, J=8.5Hz),
9.34 (1H, t, J=5.8Hz)

(3) 5-(4-Acetylphenyl)-3-[[2-(1-benzylpiperidin-4-yl)-ethyl]carbamoyl]-1,2,4-oxadiazole fumarate

mp : 197-198°C

IR (Nujol) : 3325, 1680 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.10-1.60 (5H, m), 1.70-1.95 (2H, m), 2.10-2.35 (2H, m), 2.67 (3H, s), 2.90-3.10 (2H, m), 3.30-3.45 (2H, m), 3.72 (2H, s), 6.59 (2H, s), 7.30-7.40 (5H, m), 8.19 (2H, d, J=8.6Hz), 8.28 (2H, d, J=8.6Hz), 9.13 (1H, t, J=5.8Hz)

Elemental Analysis Calcd. for $C_{25}H_{28}N_4O_3 \cdot C_4H_4O_4$:

C 63.49, H 5.87, N 10.21

Found : C 63.47, H 6.08, N 10.13

10

(4) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate

mp : 235-236°C (dec.)

IR (Nujol) : 3280, 2230, 1680 cm^{-1}

15

NMR (DMSO- d_6 , δ) : 1.10-1.60 (5H, m), 1.70-1.80 (2H, m), 2.10-2.30 (2H, m), 2.90-3.05 (2H, m), 3.30-3.40 (2H, m), 3.70 (2H, s), 6.58 (2H, s), 7.30-7.40 (5H, m), 8.14 (2H, d, J=6.8Hz), 8.31 (2H, d, J=6.8Hz), 9.13 (1H, t, J=5.7Hz)

20

(5) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-[(E)-2-(4-nitrophenyl)ethenyl]-1,2,4-oxadiazole hydrochloride

mp : 234-236°C (dec.)

25 IR (Nujol) : 3230, 1685, 1340 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.40-2.00 (7H, m), 2.6-3.5 (6H, m), 4.23 (2H, s), 7.4-7.5 (3H, m), 7.62 (2H, s), 7.67 (1H, d, J=16.4Hz), 8.06 (1H, d, J=16.4Hz), 8.14 (2H, d, J=8.9Hz), 8.30 (2H, d, J=8.9Hz), 9.10 (1H, t, J=5.7Hz), 10.90 (1H, br)

30

(6) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-[(4-nitrophenyl)methyl]-1,2,4-oxadiazol fumarate

mp : 135-136°C

35 IR (Nujol) : 3320, 1685 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.5 (5H, m), 1.6-1.8 (2H, m),
2.1-2.3 (2H, m), 2.8-3.0 (2H, m), 3.1-3.3 (2H,
m), 3.70 (2H, s), 4.64 (2H, s), 6.59 (2H, s)

- 5 (7) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-cyanophenyl)-1,3,4-oxadiazole fumarate

mp : 188-190°C (dec.)

IR (Nujol) : 3310, 2230, 1710, 1685 cm^{-1}

10 NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.25 (2H, m), 2.8-3.0 (2H, m), 3.2-3.4 (2H,
m), 3.65 (2H, s), 6.59 (2H, s), 7.34 (5H, s),
8.12 (2H, d, $J=8.5\text{Hz}$), 8.24 (2H, d, $J=8.5\text{Hz}$),
9.41 (1H, t, $J=5.8\text{Hz}$)

Elemental Analysis Calcd. for $\text{C}_{28}\text{H}_{29}\text{N}_5\text{O}_6$:

15 C 63.26, H 5.49, N 13.17

Found : C 63.26, H 5.49, N 13.19

- (8) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-nitrophenyl)-1,3,4-oxadiazole fumarate

20 mp : 200-201°C (dec.)

IR (Nujol) : 3300, 1695, 1160 cm^{-1}

25 NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.1-2.3 (2H, m), 2.85-3.1 (2H, m), 3.2-3.4 (2H,
m), 3.71 (2H, s), 6.58 (2H, s), 7.2-7.4 (5H, m),
8.34 (2H, d, $J=8.9\text{Hz}$), 8.46 (2H, d, $J=8.9\text{Hz}$),
9.44 (1H, t, $J=5.7\text{Hz}$)

Elemental Analysis Calcd. for $\text{C}_{27}\text{H}_{29}\text{N}_5\text{O}_8$:

C 58.79, H 5.29, N 12.69

Found : C 58.49, H 5.27, N 12.60

30

- (9) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methylsulfonylphenyl)-1,3,4-oxadiazole hydrochloride

mp : 180-182°C

IR (Nujol) : 3360, 1690, 1150 cm^{-1}

35 NMR (DMSO- d_6 , δ) : 1.40-2.00 (7H, m), 2.70-3.50 (6H,

m), 3.33 (3H, s), 4.20-4.40 (2H, m), 7.40-7.55 (3H, m), 7.60-7.70 (2H, m), 8.19 (2H, d, J=8.5Hz), 8.32 (2H, d, J=8.5Hz), 9.51 (1H, t, J=5.8Hz), 10.60-10.80 (1H, br)

5

(10) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methylsulfinylphenyl)-1,3,4-oxadiazole hydrochloride
mp : 159-161°C

IR (Nujol) : 3325, 1680, 1050 cm^{-1}

10 NMR (DMSO- d_6 , δ) : 1.40-2.00 (7H, m), 2.83 (3H, m), 2.70-3.50 (6H, m), 4.20-4.40 (2H, m), 7.40-7.50 (3H, m), 7.55-7.70 (2H, m), 7.95 (2H, d, J=8.5Hz), 8.25 (2H, d, J=8.5Hz), 9.45 (1H, t, J=5.9Hz), 10.50-10.80 (1H, br)

15

(11) 2-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-methylthiophenyl)-1,3,4-oxadiazole fumarate
mp : 147-148°C (dec.)

IR (Nujol) : 1680, 1645, 1600 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 1.20-1.60 (5H, m), 1.70-1.85 (2H, m), 2.10-2.30 (2H, m), 2.57 (3H, s), 2.90-3.00 (2H, m), 3.20-3.40 (2H, m), 3.69 (2H, s), 6.59 (2H, s), 7.30-7.40 (5H, m), 7.48 (2H, d, J=8.6Hz), 7.98 (2H, d, J=8.6Hz), 9.34 (1H, t, J=5.7Hz)

25

Example 12

A mixture of 3-ethoxycarbonyl-5-(4-cyanophenyl)-1,2,4-oxadiazole (2.0 g) and 2-(1-tert-butoxycarbonyl-30 piperidin-4-yl)ethylamine in N,N-dimethylformamide (1 ml) was heated at 120°C for 5 hours. The mixture was dissolved with ethyl acetate, washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was recrystallized from ethanol to afford 3-[[2-(1-tert-35 butoxycarbonylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-

cyanophenyl)-1,2,4-oxadiazole (2.6 g).

mp : 138-139°C

IR (Nujol) : 3260, 2230, 1685 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.00-1.07 (2H, m), 1.39 (9H, s),
1.46-1.48 (3H, m), 1.66-1.71 (2H, m), 2.65-2.68
(2H, m), 3.32-3.34 (2H, m), 3.89-3.95 (2H, m),
8.14 (2H, d, $J=8.4\text{Hz}$), 8.31 (2H, d, $J=8.4\text{Hz}$),
9.10-9.16 (1H, m)

Elemental Analysis Calcd. for $\text{C}_{22}\text{H}_{27}\text{N}_5\text{O}_4$:

10 C 62.10, H 6.39, N 16.45

Found : C 61.84, H 6.42, N 16.23

Example 13

15 To a solution of 3-[[2-(1-tert-butoxycarbonyl-
piperidin-4-yl)ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-
oxadiazole (2.5 g) in dioxane (30 ml) was added 4N
hydrochloric acid in dioxane (13 ml) under ice cooling.
After stirring for 5 hours at ambient temperature, the
mixture was evaporated in vacuo. The residue was
20 recrystallized from ethanol-ether to afford
3-[[2-(piperidin-4-yl)ethyl]carbamoyl]-5-(4-
cyanophenyl)-1,2,4-oxadiazole hydrochloride (1.71 g).

mp : 257-258°C (dec.)

IR (Nujol) : 3250, 2230, 1680 cm^{-1}

25 NMR (DMSO- d_6 , δ) : 1.32-1.60 (5H, m), 1.82-1.89 (2H,
m), 2.78-2.83 (2H, m), 3.20-3.49 (4H, m), 8.14
(2H, d, $J=8.4\text{Hz}$), 8.32 (2H, d, $J=8.4\text{Hz}$),
8.84-9.01 (2H, br), 9.18 (1H, m)

Mass (m/z) : 326 (M^+ of free compound)

30

Example 14

The following compounds were obtained according to a
similar manner to that of Example 6-(1).

35 (1) 3-((1-Benzylpiperidin-4-yl)carbamoyl)-5-(4-

nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 244-246°C (dec.)

IR (Nujol) : 3230, 1700, 1680, 1650 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.68-1.78 (4H, m), 2.15-2.25 (2H, m), 2.89-2.95 (2H, m), 3.60 (2H, s), 3.82-3.86 (1H, m), 6.61 (2H, s), 7.28-7.36 (5H, m), 8.40 (2H, d, $J=9.2\text{Hz}$), 8.48 (2H, d, $J=9.2\text{Hz}$), 9.11 (1H, d, $J=8.0\text{Hz}$)

10 Elemental Analysis Calcd. for $\text{C}_{21}\text{H}_{21}\text{N}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:
C 57.35, H 4.81, N 13.37
Found : C 57.45, H 4.65, N 13.21

(2) 3-((1-Benzylpiperidin-4-yl)methylcarbamoyl)-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

15 mp : 218-220°C (dec.)

IR (Nujol) : 3380, 1700, 1680 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 1.26-1.31 (2H, m), 1.67-1.73 (3H, m), 2.12-2.23 (2H, m), 2.91-2.97 (2H, m), 3.18-3.25 (2H, m), 3.67 (2H, s), 6.59 (2H, s), 7.30-7.36 (5H, m), 8.40 (2H, d, $J=9.0\text{Hz}$), 8.48 (2H, d, $J=9.0\text{Hz}$), 9.17-9.21 (1H, m)

Mass (m/z) : 421 (M^+ of free compound)

25 (3) 3-[(3-(1-Benzylpiperidin-4-yl)propyl)carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 204-205°C

IR (Nujol) : 3300, 1700, 1690 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.20-1.30 (5H, m), 1.37-1.70 (4H, m), 2.12-2.22 (2H, m), 2.90-2.96 (2H, m), 3.26-3.29 (2H, m), 3.66 (2H, s), 6.58 (2H, s), 7.30-7.35 (5H, m), 8.40 (2H, d, $J=9.1\text{Hz}$), 8.48 (2H, d, $J=9.1\text{Hz}$), 9.13-9.17 (1H, m)

Mass (m/z) : 448 (M^+ of free compound - 1)

35 (4) 3-[(2-(1-Benzylpiperidin-4-yl)ethyl)carbamoyl]-5-(2-

nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 230-231°C

IR (Nujol) : 3300, 1710, 1680 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.17-1.50 (5H, m), 1.68-1.74 (2H, m), 2.04-2.14 (2H, m), 2.85-2.91 (2H, m), 3.30-3.39 (2H, m), 3.60 (2H, s), 6.59 (2H, s), 7.26-7.35 (5H, m), 7.99-8.06 (2H, m), 8.11-8.16 (1H, m), 8.27-8.32 (1H, m), 9.15 (1H, m)

Mass (m/z) : 434 (M^+ of free compound - 1)

10 Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{25}\text{N}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:
C 58.79, H 5.29, N 12.69
Found : C 58.85, H 5.31, N 12.50

15 (5) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-chlorophenyl)-1,2,4-oxadiazole fumarate

mp : 220-222°C

IR (Nujol) : 3300, 1710, 1680 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 1.24-1.48 (5H, m), 1.72-1.78 (2H, m), 2.19-2.24 (2H, m), 2.94-3.00 (2H, m), 3.28-3.34 (2H, m), 3.74 (2H, s), 6.59 (2H, s), 7.30-7.47 (5H, m), 7.75 (2H, d, $J=8.8\text{Hz}$), 8.16 (2H, d, $J=8.8\text{Hz}$), 9.09 (1H, m)

Mass : (m/z) : 426 (M^+ of free compound)

25 Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{25}\text{ClN}_4\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:
C 59.94, H 5.40, N 10.35
Found : C 59.81, H 5.39, N 10.22

(6) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-methyl-1,2,4-oxadiazole fumarate

30 mp : 116-118°C (dec.)

IR (Nujol) : 3260, 1700, 1680 cm^{-1}

35 NMR (DMSO- d_6 , δ) : 1.17-1.43 (5H, m), 1.68-1.73 (2H, m), 2.10-2.20 (2H, m), 2.65 (3H, s), 2.89-2.94 (2H, m), 3.25-3.28 (2H, m), 3.66 (2H, s), 6.58 (2H, s), 7.25-7.35 (5H, m), 8.96 (1H, m)

- (7) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-pyridyl)-1,2,4-oxadiazole fumarate
mp : 185-186°C
IR (Nujol) : 3330, 1700, 1660 cm^{-1}
5 NMR (DMSO- d_6 , δ) : 1.21-1.32 (5H, m), 1.48-1.51 (2H, m), 1.71-1.77 (2H, m), 2.91-2.97 (2H, m), 3.28-3.43 (2H, m), 3.69 (2H, s), 6.59 (2H, s), 7.29-7.35 (5H, m), 8.06 (2H, d, $J=6.1\text{Hz}$), 8.91 (2H, d, $J=6.1\text{Hz}$), 9.14 (1H, m)
10 Mass (m/z) : 390 (M^+ of free compound - 1)
- (8) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-fluorophenyl)-1,2,4-oxadiazole fumarate
mp : 188-190°C
15 IR (Nujol) : 3260, 1700, 1670 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.20-1.50 (5H, m), 1.71-1.76 (2H, m), 2.12-2.23 (2H, m), 2.90-2.96 (2H, m), 3.30-3.37 (2H, m), 3.67 (2H, s), 6.59 (2H, s), 7.28-7.35 (5H, m), 7.48-7.57 (2H, m), 8.19-8.26 (2H, m), 9.06 (1H, m)
20 Mass (m/z) : 407 (M^+ of free compound - 1)
- (9) 3-[[2-{1-(3-Methoxybenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate
25 mp : 219-221°C
IR (Nujol) : 3280, 1700, 1670 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.21-1.51 (5H, m), 1.70-1.76 (2H, m), 2.09-2.20 (2H, m), 2.89-2.95 (2H, m), 3.32-3.46 (2H, m), 3.62 (2H, s), 3.74 (3H, s), 6.59 (2H, s), 6.84-6.92 (3H, m), 7.22-7.30 (1H, m), 8.40 (2H, d, $J=9.1\text{Hz}$), 8.48 (2H, d, $J=9.1\text{Hz}$), 9.12-9.18 (1H, m)
30 Mass (m/z) : 464 (M^+ of free compound - 1)
Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{27}\text{N}_5\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$:
35 C 57.82, H 5.37, N 12.04
Found : C 57.75, H 5.46, N 11.95

(10) 3-[[2-(1-Benzylpiperazin-4-yl)ethyl]carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 182-184°C

IR (Nujol) : 3200, 1685, 1620 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 2.42-2.56 (7H, m), 3.41-3.44 (1H, m), 3.48 (2H, s), 3.80-4.10 (4H, br), 6.59 (1H, s), 7.24-7.33 (5H, m), 8.40 (2H, d, $J=9.1\text{Hz}$), 8.49 (2H, d, $J=9.1\text{Hz}$), 8.99-9.02 (1H, m)

Mass (m/z) : 436 (M^+ of free compound)

10

(11) 3-[[2-(1-Benzylpiperidin-4-yl)ethyl]carbamoyl]-5-(2-cyanothiophen-5-yl)-1,2,4-oxadiazole fumarate

mp : 204-205°C

IR (Nujol) : 3300, 2220, 1700, 1670 cm^{-1}

15 NMR (DMSO- d_6 , δ) : 1.23-1.49 (5H, m), 1.69-1.74 (2H, m), 2.05-2.20 (2H, m), 2.88-2.94 (2H, m), 3.29-3.32 (2H, m), 3.64 (2H, s), 6.59 (2H, s), 7.28-7.35 (5H, m), 8.19 (2H, s), 9.12-9.16 (1H, m)

20 Mass (m/z) : 422 (M^+ of free compound + 1)

Elemental Analysis Calcd. for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}_2\text{S}\cdot\text{C}_4\text{H}_4\text{O}_4$:
C 58.09, H 5.06, N 13.02
Found : C 58.19, H 5.00, N 12.88

25 (12) 3-[[2-(1-(4-Fluorobenzyl)piperidin-4-yl)ethyl]-carbamoyl]-5-(4-pyridyl)-1,2,4-oxadiazole fumarate

mp : 182-183°C

IR (Nujol) : 3260, 1700, 1670 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 1.31-1.49 (5H, m), 1.74-1.91 (2H, m), 2.24-2.35 (2H, m), 2.96-3.02 (2H, m), 3.32-3.35 (2H, m), 3.77 (2H, s), 6.60 (2H, s), 7.19 (2H, dd, $J=8.7, 8.7\text{Hz}$), 7.42 (2H, dd, $J=5.7, 8.7\text{Hz}$), 8.07 (2H, d, $J=5.8\text{Hz}$), 8.93 (2H, d, $J=5.8\text{Hz}$), 9.15 (1H, m)

35 Mass (m/z) : 408 (M^+ of free compound - 1)

(13) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-fluorophenyl)-1,2,4-oxadiazole
fumarate

mp : 188-190°C

5 IR (Nujol) : 3220, 1700, 1660 cm⁻¹

NMR (DMSO-d₆, δ) : 1.23-1.48 (5H, m), 1.72-1.78 (2H,
m), 2.17-2.80 (2H, m), 2.92-2.98 (2H, m),
3.31-3.44 (2H, m), 3.71 (2H, s), 6.59 (2H, s),
7.18 (2H, dd, J=8.8, 8.8Hz), 7.40 (2H, dd, J=5.7,
10 8.8Hz), 7.52 (2H, dd, J=8.8, 8.8Hz), 8.23 (2H,
dd, J=5.7, 8.8Hz), 9.07 (1H, m)

Mass (m/z) : 425 (M⁺ of free compound - 1)

Elemental Analysis Calcd. for C₂₃H₂₄F₂N₄O₂·C₄H₄O₄ :

C 59.77, H 5.20, N 10.32

15 Found : C 59.33, H 5.31, N 10.19

(14) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 215-216°C

20 IR (Nujol) : 3370, 1700, 1670 cm⁻¹

NMR (DMSO-d₆, δ) : 1.17-1.51 (5H, m), 1.69-1.75 (2H,
m), 2.02-2.13 (2H, m), 2.84-2.90 (2H, m),
3.31-3.34 (2H, m), 3.58 (2H, s), 6.59 (2H, s),
7.16 (2H, dd, J=8.8, 8.8Hz), 7.37 (2H, dd, J=5.7,
25 8.8Hz), 8.40 (2H, d, J=9.0Hz), 8.49 (2H, d,
J=9.0Hz), 9.14 (1H, m)

Mass (m/z) : 453 (M⁺ of free compound)

Elemental Analysis Calcd. for C₂₃H₂₄FN₅O₄·C₄H₄O₄ :

C 56.93, H 4.95, N 12.29

30 Found : C 56.80, H 4.91, N 12.23

(15) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate

mp : 233-235°C (dec.)

35 IR (Nujol) : 3280, 2230, 1720, 1670 cm⁻¹

NMR (DMSO- d_6 , δ) : 1.19-1.29 (5H, m), 1.47-1.51 (2H, m), 2.07-2.18 (2H, m), 2.87-2.92 (2H, m), 3.31-3.34 (2H, m), 3.62 (2H, s), 6.59 (2H, s), 7.16 (2H, dd, $J=8.5$, 8.5Hz), 7.38 (2H, dd, $J=5.7$, 8.5Hz), 8.14 (2H, d, $J=8.4$ Hz), 8.31 (2H, d, $J=8.4$ Hz), 9.12 (1H, m)

Mass (m/z) : 432 (M^+ of free compound)

Elemental Analysis Calcd. for $C_{24}H_{24}FN_5O_2 \cdot C_4H_4O_4$:

C 61.19, H 5.13, N 12.74
Found : C 61.16, H 5.02, N 12.65

(16) 5-(4-Acetylphenyl)-3-[[2-{1-(4-fluorobenzyl)piperidin-4-yl}ethyl]carbamoyl]-1,2,4-oxadiazole fumarate

mp : 163-164°C

IR (Nujol) : 3275, 1690, 1260 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.0-1.6 (5H, m), 1.6-1.8 (2H, m), 2.05-2.25 (2H, m), 2.67 (3H, s), 2.8-3.0 (2H, m), 3.2-3.4 (2H, m), 3.63 (2H, s), 6.59 (2H, s), 7.16 (2H, dd, $J=8.8$, 8.8Hz), 7.38 (2H, dd, $J=8.8$, 5.8Hz), 8.19 (2H, d, $J=8.6$ Hz), 8.29 (2H, d, $J=8.6$ Hz), 9.11 (1H, t, $J=5.8$ Hz)

(17) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-mesylphenyl)-1,2,4-oxadiazole

mp : 174-175°C

IR (Nujol) : 3350, 1665, 1140, 960, 780 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.0-1.4 (3H, m), 1.4-1.6 (2H, m), 1.6-1.75 (2H, m), 1.8-2.0 (2H, m), 2.7-2.85 (2H, m), 3.2-3.4 (2H, m), 3.41 (2H, s), 7.12 (2H, dd, $J=8.8$, 8.8Hz), 7.31 (2H, dd, $J=8.8$, 5.8Hz), 8.21 (2H, d, $J=8.6$ Hz), 8.40 (2H, d, $J=8.6$ Hz), 9.13 (1H, t, $J=5.8$ Hz)

(18) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-methylsulfinylphenyl)-1,2,4-

oxadiazole fumarate

mp : 178-180°C

IR (Nujol) : 3320, 1670, 1225 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.85 (3H, s), 2.8-3.0 (2H, m),
3.2-3.4 (2H, m), 3.59 (2H, s), 6.59 (2H, s), 7.16
(2H, dd, $J=8.9$, 8.9Hz), 7.36 (2H, dd, $J=8.9$,
5.8Hz), 7.97 (2H, d, $J=8.4\text{Hz}$), 8.33 (2H, d,
 $J=8.4\text{Hz}$), 9.10 (1H, t, $J=5.8\text{Hz}$)

10 Elemental Analysis Calcd. for $\text{C}_{28}\text{H}_{31}\text{FN}_4\text{O}_7\text{S}$:
C 57.32, H 5.32, N 9.55
Found : C 57.39, H 5.40, N 9.50

15 (19) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-methylthiophenyl)-1,2,4-oxadiazole
fumarate

mp : 194-195°C (dec.)

IR (Nujol) : 3275, 1670, 1600, 980 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.58 (3H, s), 2.8-3.0 (2H, m),
3.3-3.4 (2H, m), 3.62 (2H, s), 6.59 (2H, s), 7.16
(2H, dd, $J=8.8$, 8.8Hz), 7.37 (2H, dd, $J=8.8$,
5.7Hz), 7.51 (2H, d, $J=8.6\text{Hz}$), 8.05 (2H, d,
 $J=8.6\text{Hz}$), 9.04 (1H, d, $J=5.8\text{Hz}$)

25

(20) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-trifluoromethylphenyl)-1,2,4-
oxadiazole fumarate

mp : 192-194°C

30 IR (Nujol) : 3300, 1700, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.22-1.48 (5H, m), 1.72-1.77 (2H,
m), 2.15-2.25 (2H, m), 2.90-2.96 (2H, m),
3.32-3.35 (2H, m), 3.69 (2H, s), 6.60 (2H, s),
7.13-7.22 (2H, m), 7.37-7.44 (2H, m), 8.05 (2H,
35 d, $J=8.3\text{Hz}$), 8.35 (2H, d, $J=8.3\text{Hz}$), 9.11-9.15
(1H, m)

Mass (m/z) : 477 (M^+ of free compound + 1)

(21) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(2-cyanothiophen-5-yl)-1,2,4-oxadiazole
fumarate

NMR (DMSO- d_6 , δ) : 1.40-1.67 (7H, m), 2.00-2.15 (2H,
m), 2.82-2.88 (2H, m), 3.32-3.40 (2H, m), 3.56
(2H, s), 6.58 (2H, s), 7.11-7.19 (2H, m),
7.30-7.38 (2H, m), 8.19 (2H, s), 9.10-9.16 (1H,
m)

Mass (m/z) : 440 (M^+ of free compound + 1)

(22) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-[(E)-2-(4-nitrophenyl)vinyl]-1,2,4-
oxadiazole fumarate

mp : 195-198°C (dec.)

IR (Nujol) : 3325, 1680, 1230 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.0-1.6 (5H, m), 1.6-1.8 (2H, m),
1.9-2.1 (2H, m), 2.7-2.9 (2H, m), 3.2-3.4 (2H,
m), 3.54 (2H, s), 6.60 (2H, s), 7.15 (2H, dd,
 $J=8.7, 8.7\text{Hz}$), 7.36 (2H, dd, $J=5.7, 8.7\text{Hz}$), 7.67
(1H, d, $J=16.4\text{Hz}$), 8.07 (1H, d, $J=16.4\text{Hz}$), 8.12
(2H, d, $J=8.8\text{Hz}$), 8.30 (2H, d, $J=8.8\text{Hz}$), 9.03
(1H, t, $J=5.8\text{Hz}$)

(23) 3-[[2-(1-Methylpiperidin-4-yl)ethyl]carbamoyl]-5-(4-
nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 195-198°C (dec.)

IR (Nujol) : 3320, 1700, 1680 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.40-1.55 (5H, m), 1.82-1.87 (2H,
m), 2.52 (3H, s), 2.57-2.72 (2H, m), 3.20-3.46
(4H, m), 6.53 (2H, s), 8.40 (2H, d, $J=9.0\text{Hz}$),
8.49 (2H, d, $J=9.0\text{Hz}$), 9.17-9.22 (1H, m)

Elemental Analysis Calcd. for $\text{C}_{17}\text{H}_{21}\text{N}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 53.05, H 5.29, N 14.72

Found : C 52.85, H 5.33, N 14.54

(24) 3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-[(E)-2-(4-cyanophenyl)vinyl]-1,2,4-
oxadiazole fumarate

mp : 220-221°C

5 IR (Nujol) : 3300, 2220, 1710, 1680, 1640 cm⁻¹

NMR (DMSO-d₆, δ) : 1.18-1.49 (5H, m), 1.69-1.75 (2H,
m), 2.07-2.18 (2H, m), 2.87-2.92 (2H, m),
3.29-3.32 (2H, m), 3.62 (2H, s), 6.59 (2H, s),
7.16 (2H, dd, J=8.8, 8.8Hz), 7.37 (2H, dd, J=5.7,
10 8.8Hz), 7.61 (1H, d, J=16.4Hz), 7.95 (2H, d,
J=8.5Hz), 8.02 (1H, d, J=16.4Hz), 8.05 (2H, d,
J=8.5Hz), 8.99-9.05 (1H, m)

(25) 2-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
15 carbamoyl]-5-(4-cyanophenyl)-1,3,4-oxadiazole fumarate

mp : 164-165°C

IR (Nujol) : 3300, 2225, 1685 cm⁻¹

NMR (DMSO-d₆, δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.8-2.95 (2H, m), 3.3-3.4 (2H,
20 m), 3.58 (2H, s), 6.58 (2H, s), 7.15 (2H, dd,
J=8.8, 8.8Hz), 7.36 (2H, dd, J=8.8, 5.8Hz), 8.11
(2H, d, J=8.6Hz), 8.24 (2H, d, J=8.6Hz), 9.40
(1H, t, J=5.8Hz)

25 (26) 2-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-5-(4-nitrophenyl)-1,3,4-oxadiazole fumarate

mp : 191-192°C (dec.)

IR (Nujol) : 3300, 1690, 1340 cm⁻¹

NMR (DMSO-d₆, δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.8-3.0 (2H, m), 3.3-3.5 (2H,
30 m), 3.62 (2H, s), 6.59 (2H, s), 7.16 (2H, dd,
J=8.8, 8.8Hz), 7.37 (2H, dd, J=8.8, 5.9Hz), 8.34
(2H, d, J=8.9Hz), 8.46 (2H, d, J=8.9Hz), 9.43
(1H, t, J=5.8Hz)

(27) 2-[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl-5-(mesylphenyl)-1,3,4-oxadiazole

mp : 174-175°C

IR (Nujol) : 3350, 1680, 1155 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.0-1.4 (3H, m), 1.4-1.6 (2H, m),
1.6-1.8 (2H, m), 1.8-2.0 (2H, m), 2.7-2.9 (2H,
m), 3.33 (3H, s), 3.2-3.4 (2H, m), 3.42 (2H, s),
7.12 (2H, dd, J=8.8, 8.8Hz), 7.32 (2H, dd, J=5.8,
8.8Hz), 8.18 (2H, d, J=8.6Hz), 8.33 (2H, d,
10 J=8.6Hz), 9.41 (1H, t, J=5.8Hz)

(28) 5-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]-3-(4-nitrophenyl)-1,2,4-oxadiazole fumarate
mp : 229-231°C (dec.)

15 IR (Nujol) : 1680, 970 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.1-1.6 (5H, m), 1.6-1.8 (2H, m),
2.0-2.2 (2H, m), 2.8-3.0 (2H, m), 3.3-3.45 (2H,
m), 3.59 (2H, s), 6.59 (2H, s), 7.16 (2H, dd,
J=8.9, 8.7Hz), 7.37 (2H, dd, J=8.7, 5.8Hz), 8.32
20 (2H, dd, J=7.0, 2.2Hz), 8.46 (2H, dd, J=7.0,
2.2Hz), 9.54 (1H, t, J=5.8Hz)

(29) 3-[[2-(1-tert-Butoxycarbonylpiperidin-4-yl)ethyl]-
carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole

25 mp : 139-141°C

IR (Nujol) : 3380, 3300, 1740, 1680, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.97-1.18 (3H, m), 1.39 (9H, s),
1.47-1.51 (2H, m), 1.66-1.72 (2H, m), 2.62-2.74
(2H, m), 3.32-3.36 (2H, m), 3.89-3.95 (2H, m),
30 8.40 (2H, d, J=9.1Hz), 8.48 (2H, d, J=9.1Hz),
9.15 (1H, t, J=5.8Hz)

(30) 3-[[2-(4-Pyridyl)ethyl]carbamoyl]-5-(4-cyanophenyl)-
1,2,4-oxadiazole

35 mp : 218-220°C

IR (Nujol) : 2220, 1680, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.91 (2H, t, $J=7.1\text{Hz}$), 3.55-3.65
(2H, m), 7.29 (2H, dd, $J=1.5, 6.0\text{Hz}$), 8.15 (2H,
d, $J=8.6\text{Hz}$), 8.29 (2H, d, $J=8.6\text{Hz}$), 8.48 (2H, dd,
5 $J=1.5, 6.0\text{Hz}$), 9.24 (1H, t, $J=5.6\text{Hz}$)

Mass (m/z) : 319 (M^+)

(31) 3-[[2-(4-Pyridyl)ethyl]carbamoyl]-5-(4-nitrophenyl)-
1,2,4-oxadiazole

10 mp : 208-209°C

IR (Nujol) : 1680, 1600 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.93 (2H, t, $J=7.1\text{Hz}$), 3.60 (2H,
m), 7.30 (2H, dd, $J=1.4, 6.0\text{Hz}$), 8.37-8.50 (6H,
m), 9.27 (1H, t, $J=5.7\text{Hz}$)

15

Example 15

The mixture of 2-acetoxy-5-(1-benzylpiperidin-4-yl)-
1-(4-nitrobenzoyloxyimino)pentylamine (1.5 g) and molecular
sieves 4A (7.5 g) in dioxane (50 ml) was refluxed for 2
20 hours. After molecular sieves were removed by filtration,
the filtrate was evaporated in vacuo. The residue was
chromatographed on silica eluting with 3% methanol in
chloroform to give 3-[1-acetoxy-4-(1-benzylpiperidin-4-yl)-
butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole (0.63 g, 43.6%).
25 The compound (74 mg) was dissolved in a solution of fumaric
acid (18 mg) in ethanol to give 3-[1-acetoxy-4-(1-
benzylpiperidin-4-yl)butyl]-5-(4-nitrophenyl)-1,2,4-oxadia-
zole fumarate (80 mg).

mp : 108-110°C

30 IR (Nujol) : 1750, 1710, 1660 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.13-1.22 (7H, m), 1.60-1.65 (2H,
m), 1.94-2.02 (2H, m), 2.08-2.10 (2H, m), 2.11
(3H, s), 2.84-2.90 (2H, m), 3.59 (2H, s), 5.91
(1H, t, $J=6.7\text{Hz}$), 6.59 (2H, s), 7.30-7.32 (5H,
35 m), 8.35 (2H, d, $J=9.1\text{Hz}$), 8.44 (2H, d, $J=9.1\text{Hz}$)

Mass (m/z) : 477 (M^+ of free compound - 1)

Example 16

5 The following compound was obtained according to a similar manner to that of Example 15.

3-{4-(1-Benzylpiperidin-4-yl)butyl}-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 157-158°C

10 IR (Nujol) : 1700, 1650 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.20-1.40 (7H, m), 1.65-1.75 (4H, m), 2.30-2.40 (2H, m), 2.75-2.82 (2H, m), 2.90-3.05 (2H, m), 3.90-3.95 (2H, m), 6.60 (2H, s), 7.25-7.40 (5H, m), 8.36-8.42 (4H, br)

15 Mass (m/z) : 420 (M^+ of free compound)

Example 17

The following compound was obtained according to a similar manner to that of Example 13.

20

3-[[2-(Piperidin-4-yl)ethyl]carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole hydrochloride

mp : 238-240°C (dec.)

IR (Nujol) : 3500, 3450, 3270, 1690, 1650 cm^{-1}

25 NMR (DMSO-d_6 , δ) : 1.34-1.60 (5H, m), 1.83-1.89 (2H, m), 2.78-2.83 (2H, m), 3.20-3.41 (4H, m), 8.40 (2H, d, $J=8.9\text{Hz}$), 8.49 (2H, d, $J=8.9\text{Hz}$), 8.92-8.96 (1H, br), 9.08-9.12 (1H, br), 9.18-9.23 (1H, m)

30 Mass (m/z) : 344 (M^+ of free compound - 1)

Example 18

(1) To a suspension of 3-[[2-{1-(4-fluorobenzyl)-4-pyridinio}ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole iodide (0.6 g) in methanol (5 ml) -

35

tetrahydrofuran (7 ml) was added sodium borohydride (41 mg) at 0°C under stirring. After stirring for 1 hour at ambient temperature, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica eluting with 3% methanol in chloroform and the fractions containing the object compound were evaporated in vacuo. The residue was dissolved in a solution of fumaric acid (106 mg) in ethanol (5 ml) to give 3-[[2-{1-(4-fluorobenzyl)-1,2,3,6-tetrahydropyridin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate (0.35 g).

mp : 209-211°C
IR (Nujol) : 3230, 2230, 1710, 1670, 1600 cm⁻¹
NMR (DMSO-d₆, δ) : 2.15-2.28 (4H, m), 2.65-2.71 (2H, m), 2.97-3.01 (2H, m), 3.37-3.50 (2H, m), 3.69 (2H, s), 5.40-5.43 (1H, br), 6.61 (2H, s), 7.16 (2H, dd, J=8.8, 8.8Hz), 7.40 (2H, dd, J=5.7, 8.8Hz), 8.15 (2H, d, J=8.6Hz), 8.30 (2H, d, J=8.6Hz), 9.06-9.12 (1H, m)
Mass (m/z) : 432 (M⁺ of free compound + 1)

The following compounds were obtained according to a similar manner to that of Example 18-(1).

(2) 3-[[2-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)ethyl]-carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate
mp : 188-189°C (dec.)
IR (Nujol) : 3200, 1700, 1680 cm⁻¹
NMR (DMSO-d₆, δ) : 2.09-2.15 (2H, br), 2.21-2.28 (2H, m), 2.60-2.66 (2H, m), 2.91-2.97 (2H, br), 3.35-3.50 (2H, m), 3.64 (2H, s), 5.39-5.43 (1H, br), 6.59 (2H, s), 7.26-7.35 (5H, m), 8.39 (2H, d, J=9.0Hz), 8.47 (2H, d, J=9.0Hz), 9.09-9.15 (1H, m)

Mass (m/z) : 434 (M^+ of free compound + 1)

(3) 3-[[2-{1-(4-Fluorobenzyl)-1,2,3,6-tetrahydropyridin-4-yl}ethyl]carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 191-193°C (dec.)

IR (Nujol) : 3230, 1700, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.11-2.17 (2H, br), 2.22-2.28 (2H, m), 2.63-2.68 (2H, m), 2.95-2.99 (2H, m), 3.39-3.50 (2H, m), 3.67 (2H, s), 5.40-5.44 (1H, br), 6.60 (2H, s), 7.15 (2H, dd, $J=8.8$, 8.8Hz), 7.38 (2H, dd, $J=5.7$, 8.8Hz), 8.39 (2H, d, $J=8.9$ Hz), 8.48 (2H, d, $J=8.9$ Hz), 9.09-9.15 (1H, m)

Mass (m/z) : 452 (M^+ of free compound + 1)

Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{22}\text{FN}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 57.14, H 4.61, N 12.34

Found : C 57.23, H 4.63, N 12.30

(4) 3-[[2-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate

mp : 216-217°C

IR (Nujol) : 3240, 2220, 1700, 1670 cm^{-1}

NMR (DMSO- d_6 , δ) : 2.11-2.17 (2H, br), 2.21-2.28 (2H, m), 2.64-2.70 (2H, m), 2.97-3.02 (2H, br), 3.35-3.47 (2H, m), 3.69 (2H, s), 5.39-5.43 (1H, br), 6.60 (2H, s), 7.28-7.36 (5H, m), 8.14 (2H, d, $J=8.6$ Hz), 8.31 (2H, d, $J=8.6$ Hz), 9.06-9.12 (1H, m)

Mass (m/z) : 414 (M^+ of free compound + 1)

Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{23}\text{N}_5\text{O}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 63.50, H 5.13, N 13.22

Found : C 63.46, H 5.17, N 13.09

Example 19

A solution of 4N hydrogen chloride in ethyl acetate

(0.56 ml) was added to a solution of 3-[[2-{1-(4-fluorobenzyl)piperidin-4-yl}ethyl]carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole (0.8 g) in ethyl acetate (20 ml) under ice cooling. The resulting precipitates were
5 filtered off, washed with diethyl ether, and dried in vacuo to give 3-[[2-{1-(4-fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole hydrochloride (0.75 g).

mp : 245-247°C

10 IR (Nujol) : 3230, 1680 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.50-1.53 (5H, m), 1.87-1.99 (2H, m), 2.81-2.85 (2H, m), 3.26-3.37 (4H, m), 4.24-4.36 (2H, m), 7.29 (2H, dd, $J=8.8$, 8.8Hz), 7.72 (2H, dd, $J=5.5$, 8.8Hz), 8.15 (2H, d, $J=8.6$ Hz), 8.31 (2H, d, $J=8.6$ Hz), 9.15-9.21 (1H, m)

15 Mass (m/z) : 433 (M^+ of free compound)

Example 20

20 To a solution of 3-[1-acetoxy-4-(1-benzylpiperidin-4-yl)butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole (0.5 g) in methanol (10 ml) was added 4N an aqueous sodium hydroxide solution (0.5 ml) at 0°C. After stirring at 0°C for 2 hours, ice water was added to the mixture and the
25 precipitates were filtrated to give 3-[1-hydroxy-4-(1-benzylpiperidin-4-yl)butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole (0.44 g). The compound (100 mg) was dissolved in a solution of fumaric acid (27 mg) in ethanol to give 3-[1-hydroxy-4-(1-benzylpiperidin-4-yl)-
30 butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate (0.1 g).

mp : 78-81°C (dec.)

IR (Nujol) : 3350, 1700, 1650 cm^{-1}

35 NMR (DMSO- d_6 , δ) : 1.20-1.40 (7H, m), 1.63-1.68 (2H, m), 1.79-1.83 (2H, m), 2.12-2.26 (2H, m), 2.91-2.96 (2H, m), 3.70 (2H, s), 4.77 (1H, t,

J=6.7Hz), 6.59 (2H, s), 7.10-7.35 (5H, m), 8.35 (2H, d, J=9.0Hz), 8.45 (2H, d, J=9.0Hz)
Mass (m/z) : 436 (M^+ of free compound)

5 Example 21

 The mixture of 3-[1-hydroxy-4-(1-benzylpiperidin-4-yl)butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole (0.28 g), N,N-dicyclohexylcarbodiimide (0.66 g) and o-phosphoric acid (0.31 g) in dimethyl sulfoxide (5 ml) was stirred overnight
10 at ambient temperature and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica eluting with 3% methanol in chloroform to give 3-[1-oxo-4-(1-benzylpiperidin-4-yl)-
15 butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole as an oil (0.21 g). The oil was dissolved in a solution of fumaric acid (48 mg) in ethanol and the crystals were filtered off to give 3-[1-oxo-4-(1-benzylpiperidin-4-yl)butyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate (0.18 g).

20 mp : 159-161°C

 IR (Nujol) : 1710, 1650 cm^{-1}

 NMR (DMSO- d_6 , δ) : 1.25-1.35 (5H, m), 1.71-1.76 (4H, m), 2.32-2.44 (2H, m), 3.00-3.15 (4H, m), 3.83 (2H, s), 6.60 (2H, s), 7.38-7.41 (5H, m), 8.41 (2H, d, J=9.1Hz), 8.47 (2H, d, J=9.1Hz)

25 Mass (m/z) : 434 (M^+ of free compound)

 Elemental Analysis Calcd. for $\text{C}_{24}\text{H}_{26}\text{N}_4\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:

 C 61.08, H 5.49, N 10.17

 Found : C 60.87, H 5.47, N 10.05

30

Example 22

 A mixture of paraformaldehyde (70 mg), copper(I) chloride (10 mg) and pyrrolidine (0.1 ml) in dioxane (2 ml) was stirred at ambient temperature. After stirring for 30
35 minutes, a solution of 3-((2-propynyl)carbamoyl)-5-(4-

nitrophenyl)-1,2,4-oxadiazole (300 mg) in dioxane (3 ml) was added dropwise to the mixture and stirred overnight. The resulting precipitates were removed out by filtration and the filtrate was evaporated in vacuo. The residue was chromatographed on silica eluting with 3% methanol in chloroform and the fractions containing the object compound were evaporated in vacuo. The residue was dissolved in ethanol and 4N hydrogen chloride in ethanol was added, and the precipitates was filtered off to give 3-[[4-(pyrrolidin-1-yl)-2-butynyl]carbamoyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole hydrochloride (0.2 g).

mp : 214-216°C (dec.)

IR (Nujol) : 3170, 2550, 2450, 1695 cm^{-1}

NMR (DMSO- d_6 , δ) : 1.94-1.97 (4H, m), 3.18-3.56 (4H, m), 4.10 (2H, s), 4.20 (2H, d, $J=5.4\text{Hz}$), 8.40 (2H, d, $J=9.1\text{Hz}$), 8.50 (2H, d, $J=9.1\text{Hz}$), 9.73 (1H, t, $J=5.4\text{Hz}$)

Mass (m/z) : 355 (M^+ of free compound)

20 Example 23

(1) To a mixture of 3-[(E)-2-carboxyvinyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole (0.25 g), 2-(1-benzylpiperidin-4-yl)ethylamine (0.23 g) and 1-hydroxybenzotriazole hydrate (0.16 g) in N,N-dimethylformamide (5 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.20 ml) at 5°C. After stirring for 1 hour at ambient temperature, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica eluting with 2% methanol in chloroform and the fractions containing the object compound were evaporated in vacuo. The residue was dissolved in a solution of fumaric acid (71 mg) in ethanol to give 3-[(E)-2-[[2-(1-benzylpiperidin-4-yl)ethyl]-

carbamoyl]vinyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole
fumarate (0.32 g).

mp : 231-232°C

IR (Nujol) : 3240, 2220, 1700, 1670, 1640 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 1.22-1.50 (5H, m), 1.67-1.73 (2H,
m), 2.11-2.22 (2H, m), 2.90-2.96 (2H, m),
3.20-3.30 (2H, m), 3.66 (2H, s), 6.59 (2H, s),
7.20 (1H, d, $J=15.5\text{Hz}$), 7.28-7.39 (6H, m), 8.13
10 (2H, d, $J=8.6\text{Hz}$), 8.28 (2H, d, $J=8.6\text{Hz}$),
8.53-8.56 (1H, m)

Mass (m/z) : 442 (M^+ of free compound + 1)

The following compounds were obtained according to a
similar manner to that of Example 23-(1).

15

(2) 3-[(E)-2-[(1-Benzylpiperidin-4-yl)carbamoyl]-
vinyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 266-268°C

IR (Nujol) : 3240, 1700, 1670, 1650 cm^{-1}

20 NMR (DMSO- d_6 , δ) : 1.44-1.56 (2H, m), 1.80-1.86 (2H,
m), 2.14-2.25 (2H, m), 2.82-2.87 (2H, m), 3.57
(2H, s), 3.65-3.75 (1H, m), 6.61 (2H, s), 7.24
(1H, d, $J=15.5\text{Hz}$), 7.33-7.40 (6H, m), 8.36 (2H,
d, $J=9.0\text{Hz}$), 8.48 (2H, d, $J=9.0\text{Hz}$), 8.55 (1H, d,
25 $J=7.6\text{Hz}$)

Mass (m/z) : 434 (M^+ of free compound + 1)

Elemental Analysis Calcd. for $\text{C}_{23}\text{H}_{23}\text{N}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:

C 59.01, H 4.95, N 12.74

Found : C 58.80, H 4.93, N 12.67

30

(3) 3-[(E)-2-[(2-(1-Benzylpiperidin-4-yl)ethyl)carbamoyl]-
vinyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole fumarate

mp : 221-223°C

IR (Nujol) : 3260, 1700, 1660, 1630 cm^{-1}

35 NMR (DMSO- d_6 , δ) : 1.26-1.42 (5H, m), 1.68-1.74 (2H,

- m), 2.12-2.23 (2H, m), 2.91-2.96 (2H, m),
3.22-3.25 (2H, m), 3.67 (2H, s), 6.59 (2H, s),
7.22 (1H, d, J=15.6Hz), 7.32-7.40 (6H, m), 8.37
(2H, d, J=9.0Hz), 8.47 (2H, d, J=9.0Hz),
8.54-8.58 (1H, m)
Mass (m/z) : 462 (M^+ of free compound + 1)
- (4) 3-[(E)-2-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]vinyl]-5-(4-nitrophenyl)-1,2,4-oxadiazole
fumarate
mp : 229-230°C
IR (Nujol) : 3250, 1700, 1660, 1630 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.25-1.42 (5H, m), 1.68-1.74 (2H,
m), 2.11-2.22 (2H, m), 2.89-2.95 (2H, m),
3.23-3.25 (2H, m), 3.66 (2H, s), 6.59 (2H, s),
7.17 (2H, dd, J=8.8, 8.8Hz), 7.21 (1H, d,
J=16.9Hz), 7.36 (1H, d, J=16.9Hz), 7.39 (2H, dd,
J=5.7, 8.8Hz), 8.36 (2H, d, J=9.0Hz), 8.47 (2H,
d, J=9.0Hz), 8.52-8.58 (1H, m)
Mass (m/z) : 480 (M^+ of free compound + 1)
Elemental Analysis Calcd. for $\text{C}_{25}\text{H}_{26}\text{FN}_5\text{O}_4 \cdot \text{C}_4\text{H}_4\text{O}_4$:
C 58.48, H 5.07, N 11.75
Found : C 58.21, H 5.19, N 11.61
- (5) 3-[(E)-2-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-
carbamoyl]vinyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole
fumarate
mp : 238-240°C
IR (Nujol) : 3260, 2230, 1700, 1670, 1630 cm^{-1}
NMR (DMSO- d_6 , δ) : 1.24-1.41 (5H, m), 1.67-1.73 (2H,
m), 2.07-2.18 (2H, m), 2.87-2.92 (2H, m),
3.22-3.25 (2H, m), 3.62 (2H, s), 6.59 (2H, s),
7.16 (2H, dd, J=8.7, 8.7Hz), 7.20 (1H, d,
J=15.3Hz), 7.35 (1H, d, J=15.3Hz), 7.35 (2H, dd,
J=5.7, 8.7Hz), 8.13 (2H, d, J=8.5Hz), 8.28 (2H,

d, J=8.5Hz), 8.52-8.57 (1H, m)

Mass (m/z) : 460 (M⁺ of free compound + 1)

Elemental Analysis Calcd. for C₂₆H₂₆FN₅O₂·C₄H₄O₄ :

C 62.60, H 5.25, N 12.16

5

Found : C 62.45, H 5.20, N 12.08

10

15

20

25

30

35

C L A I M S

1. A compound of the formula :



wherein R^1 is lower alkyl, a heterocyclic group which
may have suitable substituent(s), aryl
which may have suitable substituent(s),
10 ar(lower)alkyl which may have suitable
substituent(s), or ar(lower)alkenyl
which may have suitable substituent(s),

Q is oxadiazolediyl,

Z is bond or vinyl,

15 X is bond,

a group of the formula :



(in which R^4 is hydrogen or lower
alkyl), a group of the formula :



(in which R^8 is hydroxy or protected
hydroxy),



A is bond, lower alkylene or lower alkynylene and

M is a heterocyclic group containing at least one nitrogen atom which may have one substituent selected from the group consisting of lower alkyl, an imino protective group and ar(lower)alkyl which may have suitable substituent(s), and a pharmaceutically acceptable salt thereof.

10

2. A compound of claim 1, wherein

R^1 is lower alkyl, a heterocyclic group which may have 1 to 3 suitable substituent(s),

15

aryl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano and acyl,


20

ar(lower)alkyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl, or

25

ar(lower)alkenyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl,


30



35

X is bond,

a group of the formula :



(in which R^4 is hydrogen or lower alkyl),
a group of the formula :




(in which R^8 is hydroxy or acyloxy),



20 M is unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 4-nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s),
each of which may have one substituent selected
25 from the group consisting of lower alkyl, an imino protective group and ar(lower)alkyl which may have 1 to 3 suitable substituent(s).

3. A compound of the claim 2, wherein
30 $-R^1$ is lower alkyl; unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) or saturated heterobicyclic group of the
35 formula :



5

10

each of which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, cyano, nitro, mono(or di or tri)halo(lower)alkyl and acyl;

15

phenyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano, lower alkylsulfonyl and lower alkanoyl;

20

phenyl(lower)alkyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl; or

25

phenyl(lower)alkenyl which may have 1 to 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, nitro, mono(or di or tri)halo(lower)alkyl, cyano, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl,

30

X is bond,

a group of the formula :




35

(in which R^4 is hydrogen or lower alkyl),
a group of the formula :



(in which R^8 is hydroxy or lower alkanoyloxy),




15 M is piperidyl, piperazinyl, pyrrolidinyl,
tetrahydropyridyl or pyridyl, each of which may
have one substituent selected from the group
consisting of lower alkyl, acyl and
phenyl(lower)alkyl which may have 1 to 2
substituent(s) selected from the group
20 consisting of halogen, cyano, nitro, lower
alkyl, lower alkoxy and lower alkylthio.

4. A compound of claim 3, wherein
- 25 R^1 is lower alkyl; pyridyl, thienyl or quinuclidinyl,
each of which may have cyano;
phenyl which may have a substituent selected
from the group consisting of lower alkyl, lower
alkoxy, nitro, halogen, mono(or di or
tri)halo(lower)alkyl, lower alkylthio, lower
alkylsulfinyl, cyano, lower alkylsulfonyl and
30 lower alkanoyl;
phenyl(lower)alkyl which may have nitro; or
phenyl(lower)alkenyl which may have cyano or
nitro, and
- 35 M is piperidyl, piperazinyl, pyrrolidinyl,

tetrahydropyridyl or pyridyl, each of which may have one substituent selected from the group consisting of lower alkyl, lower alkoxy, carbonyl and phenyl(lower)alkyl which may have a substituent selected from the group consisting of halogen, cyano, nitro, lower alkyl and lower alkoxy.

5. A compound of the claim 4, wherein

R^1 is phenyl which may have a substituent selected from the group consisting of lower alkyl, lower alkoxy, nitro, halogen, mono(or di or tri)-halo(lower)alkyl, lower alkylthio, lower alkylsulfinyl, cyano, lower alkylsulfonyl and lower alkanoyl,



Z is bond,




(in which R^4 is hydrogen),

A is lower alkylene, and

M is piperidyl which has phenyl(lower)alkyl which may have a substituent selected from the group consisting of halogen, cyano, nitro, lower alkyl and lower alkoxy.

6. A compound of claim 5, which is a compound of the formula :



wherein R¹ is cyanophenyl,

A is lower alkylene, and

10 M is piperidyl having halophenyl(lower)-alkyl.

7. A compound of claim 6, which is selected from the group consisting of :

15

3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate,

20

3-[[2-{1-(3-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate,

25

3-[[2-{1-(2-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate,

30

3-[[2-{1-(4-Chlorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole fumarate and

35

3-[[2-{1-(4-Fluorobenzyl)piperidin-4-yl}ethyl]-carbamoyl]-5-(4-cyanophenyl)-1,2,4-oxadiazole hydrochloride.

8. A process for preparing a compound of the formula :



5 wherein R^1 is lower alkyl, a heterocyclic group which
may have suitable substituent(s), aryl
which may have suitable substituent(s),
ar(lower)alkyl which may have suitable
10 substituent(s), or ar(lower)alkenyl
which may have suitable substituent(s),
Q is oxadiazolediyl,
Z is bond or vinyl,
X is bond,
a group of the formula :



20 (in which R^4 is hydrogen or lower
alkyl), a group of the formula :



25 (in which R^8 is hydroxy or protected
hydroxy),



30 A is bond, lower alkylene or lower
alkynylene and
35

M is a heterocyclic group containing at least one nitrogen atom which may have one substituent selected from the group consisting of lower alkyl, an imino protective group and ar(lower)alkyl which may have suitable substituent(s),


or a salt thereof,

which comprises

(1) reacting a compound of the formula :




wherein R^1 , Q and Z are each as defined above, or its reactive derivative at the carboxy group, or a salt thereof with a compound of the formula :




wherein A and M are each as defined above, or its reactive derivative at the amino group, or a salt thereof to give a compound of the formula :



wherein R^1 , Q, Z, A and M are each as defined above, or a salt thereof, or
(2) reacting a compound of the formula :



wherein R^1 , Q and Z are each as defined above, or its reactive derivative at the amino group, or a salt thereof with a compound of the formula :




- 5 wherein A and M are each as defined above,
or its reactive derivative at the carboxy group,
or a salt thereof to give a compound of the formula :




- 10 wherein R^1 , Q, Z, A and M are each as defined above,
or a salt thereof, or
(3) reacting a compound of the formula :



- 15 wherein R^1 is as defined above, and
 R^3 is a leaving group,
20 or a salt thereof with a compound of the formula :




- 25 wherein Z, X, A and M are each as defined above,
or a salt thereof to give a compound of the formula :




- 30 wherein R^1 , Z, X, A and M are each as defined above,
or a salt thereof, or
(4) reacting a compound of the formula :

35



wherein R^1 , Q, Z, A and M are each as defined above,
or a salt thereof with a compound of the formula :


5



wherein R_{a1}^4 is lower alkyl, and
 y^1 is acid residue,

. 10

or a salt thereof to give a compound of the formula :




15

wherein R^1 , Q, Z, R_a^4 , A and M are each as defined above,

or a salt thereof, or

(5) subjecting a compound of the formula :

20



25

wherein R^1 , Q, Z, X and A are each as defined above,
 R^7 is hydrogen, (C_1-C_5) alkyl, aryl which may
 have suitable substituent(s), or
 ar (C_1-C_5) alkyl which may have suitable
 substituent(s),


30

— \bigcirc NH is a saturated heterocyclic group containing at least one nitrogen atom, and

W^{1-} is anion,

or a salt thereof to reduction reaction to give a compound of the formula :


35



wherein R^1 , R^7 , Q, Z, X, A and $\text{C}_6\text{H}_4\text{NH}$ are each as defined above,

5 or a salt thereof, or


(6) subjecting a compound of the formula :



10 wherein R^1 , Q, Z, X and A are each as defined above, and

M^1 is a heterocyclic group containing at least one nitrogen atom which has an imino protective group,

15 or a salt thereof to elimination reaction of the imino protective group to give a compound of the formula :




20 wherein R^1 , Q, Z, X and A are each as defined above, and

M^2 is a heterocyclic group containing at least one nitrogen atom,

or a salt thereof, or

25 (7) subjecting a compound of the formula :




30

wherein R^1 , Q, Z, X and A are each as defined above, R^2 is lower alkyl, an imino protective group, or ar(lower)alkyl which may have suitable substituent(s), and

35

W^{2-} is anion,

or a salt thereof to reduction reaction to give a compound of the formula :




5

wherein R^1 , Q, Z, X, A and R^2 are each as defined above,

or a salt thereof, or

10 (8) subjecting a compound of the formula :




15

wherein R^1 , Q, Z, A and M are each as defined above, and

R_a^8 is protected hydroxy,

or a salt thereof to elimination reaction of the hydroxy protective group to give a compound of the


20



25

wherein R^1 , Q, Z, A and M are each as defined above, or a salt thereof, or


(9) subjecting a compound of the formula :




30

wherein R^1 , Q, Z, A and M are each as defined above, or a salt thereof to oxidation reaction to give a compound of the formula :


35



wherein R^1 , Q, Z, A and M are each as defined above,
 or a salt thereof, or
 (10) reacting a compound of the formula :




wherein R^1 , Q, Z and X are each as defined above,
 or a salt thereof with a compound of the formula :



wherein R^2 and $\bigcirc \text{NH}$ are each as defined above,
 and

$\text{W}^{3\ominus}$ is anion,
 or a salt thereof to give a compound of the formula :



wherein R^1 , Q, Z, X, R^2 and $\bigcirc \text{NH}$ are each as
 defined above,
 or a salt thereof.

9. A pharmaceutical composition which comprises, as an
 active ingredient, a compound of claim 1 or a
 pharmaceutically acceptable salt thereof in admixture
 with pharmaceutically acceptable carriers.

10. A use of a compound of claim 1 or a pharmaceutically acceptable salt thereof as acetylcholinesterase-inhibitory agent or muscarinic agonist.
- 5 11. A method for the prophylactic or therapeutic treatment of disorders in the central nervous system and cerebrovascular disease which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to human or
10 animals.
12. A process for preparing a pharmaceutical composition which comprises admixing a compound of claim 1 or a pharmaceutically acceptable salt thereof with a
15 pharmaceutically acceptable carrier.

20

25

30

35

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07D271/06; C07D271/00;	C07D453/02; A61K31/41;	C07D413/12; A61K31/445
C07D413/06		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0 459 568 (MERCK SHARP & DOHME LTD.) 4 December 1991 see the whole document ---	1-5,8,9, 12
X	EP,A,0 402 056 (BEECHAM GROUP P.L.C.) 12 December 1990 see the whole document ---	1-5,8,9, 12
X	EP,A,0 363 085 (BEECHAM GROUP PLC) 11 April 1990 see the whole document ---	1-5,8,9, 12
X	EP,A,0 328 200 (MERCK SHARP & DOHME LTD.) 16 August 1989 see the whole document ---	1-5,8,9, 12
X	EP,A,0 323 864 (MERCK SHARP & DOHME LTD.) 12 July 1989 see the whole document ---	1-5,8,9, 12
-/--		
¹⁰ Special categories of cited documents : ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed ^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art ^{"A"} document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 15 MARCH 1993		Date of Mailing of this International Search Report 26. 03. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer ALLARD M.S.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	
X	EP,A,0 316 718 (A/S FERROSAN) 24 May 1989 see the whole document ---	1-5,8,9, 12
X	EP,A,0 301 729 (MERCK SHARP & DOHME LTD.) 1 February 1989 see the whole document ---	1-5,8,9, 12
X	EP,A,0 261 763 (BEECHAM GROUP PLC) 30 March 1988 see the whole document ---	1-5,8,9, 12
X	EP,A,0 259 621 (A/S FERROSAN) 16 March 1988 see the whole document ---	1-5,8,9, 12
X	EP,A,0 239 309 (MERCK SHARP & DOHME LTD.) 30 September 1987 see the whole document ---	1-5,8,9, 12
X	FR,A,1 481 025 (AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO) 19 May 1967 see the whole document ---	1-5,8,9, 12
X	FR,A,2 247 213 (DELALANDE S.A.) 9 May 1975 see the whole document ---	1-5,8,9, 12
X	JOURNAL OF MEDICINAL CHEMISTRY vol. 33, no. 10, October 1990, WASHINGTON US pages 2690 - 2697 L.J. STREET ET AL. 'Synthesis and Biological Activity of 1,2,4-Oxadiazole Derivatives: Highly Potent and Efficacious Agonists for Cortical Muscarinic Receptors' see the whole document ---	1-5,8,9, 12
X	ATHEROSCLEROSIS vol. 17, 1973, AMSTERDAM, NL pages 121 - 129 Y. IMAI ET AL. 'Biological Studies of AT-308. Part 1. Hypocholesterolemic effect of 1,2,4-oxadiazole derivatives in rats.' see the whole document -----	1-5,8,9, 12

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10,11 are directed to a method of treatment of the human/
animal body, the search has been carried out and based on the alleged
effects of the compounds/compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
Given the large number of unexplored compounds covered by different IPC sub-
divisions encompassed by claims 1-5, the search has been limited to those
IPC subdivisions which correspond to the actual examples of the application
(see Art. 6 PCT and PCT Search Guidelines C-III, 2.1 and 3.7). It appears
3. ☒ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/

furthermore that claims 1-5 cover such an amount of already known compounds that a complete International Search Report is not feasible.

Claims searched completely : 6,7

Claims searched incompletely: 1-5,8,9,12

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

JP 9201658
SA 68137

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 15/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0459568	04-12-91	JP-A- 4235985	25-08-92
		US-A- 5134146	28-07-92
EP-A-0402056	12-12-90	AU-A- 5625390	13-12-90
		JP-A- 3027377	05-02-91
EP-A-0363085	11-04-90	AU-A- 4242689	26-04-90
		JP-A- 2129186	17-05-90
		US-A- 5091397	25-02-92
EP-A-0328200	16-08-89	AU-A- 2986089	17-08-89
		JP-A- 1268687	26-10-89
		US-A- 4952587	28-08-90
		US-A- 5041456	20-08-91
EP-A-0323864	12-07-89	AU-A- 2779889	20-07-89
		JP-A- 2149580	08-06-90
EP-A-0316718	24-05-89	AU-A- 2460888	18-05-89
		JP-A- 1153688	15-06-89
EP-A-0301729	01-02-89	AU-B- 613383	01-08-91
		AU-A- 1973988	27-01-89
		JP-A- 1047775	22-02-89
EP-A-0261763	30-03-88	AU-B- 620783	09-01-92
		AU-B- 620307	17-12-91
		AU-A- 7131891	23-05-91
		AU-A- 7469587	07-01-88
		JP-A- 63039876	20-02-88
		US-A- 4968691	06-11-90
EP-A-0259621	16-03-88	AU-B- 603603	22-11-90
		AU-A- 7816587	31-03-88
		DE-A- 3782785	07-01-93
		JP-A- 63077877	08-04-88
		US-A- 4837241	06-06-89
		US-A- 4933353	12-06-90
		ZA-A- 8705550	08-02-88

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

JP 9201658
SA 68137

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15/03/93

Page 2

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0239309	30-09-87	AU-B- 603564	22-11-90
		AU-A- 7068687	01-10-87
		JP-A- 63017879	25-01-88
		ZA-A- 8702231	21-09-87
FR-A-1481025		GB-A- 969813	
FR-A-2247213	09-05-75	None	

EPO FORM P077

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.